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ABSTRACT
Dietary n-3 fatty acids and non-steroidal anti-inflammatory drugs (NSAIDs) 
have been shown to have cancer preventive and tumor regressive effects. Fatty acids 
and NSAIDs are substrates and inhibitors, respectively, o f cyclooxygenase-2 (COX-2), 
which is a key enzyme in the conversion o f arachidonic acids to prostaglandins.
Thus, the modulating effects o f different types o f dietary fatty acids and NSAIDs on the 
expression o f COX-2 are studied here. Results show that both n-3 and n- 6  
polyunsaturated fatty acids (PUFAs) inhibit Lipopolysaccharide (LPS)-induced COX-2 
expression and NF-tcB activation in macrophages. Results from an in vitro cell 
proliferation study indicate that growth o f  colon tumor cells is suppressed by n-3 
PUFAs as compared with n- 6  PUFAs regardless of whether COX-1 or COX-2 is 
expressed or not. These results suggest that signaling pathways through which PUFAs 
inhibit tumor cell growth and LPS-induced COX-2 expression may be different. Unlike 
the previous study in human colon carcinoma cells, NSAIDs, especially flufenamic acid 
and sulindac sulfide, upregulate the expression o f COX-2 under both the presence and 
absence of COX-2 stimulators in a normal intestinal cell line, IEC - 6  cells. The 
inhibitors of extracellular-signal-regulated protein kinase (ERK), and p38 MAP kinase 
inhibit the flufenamic acid-induced COX-2 expression, suggesting that flufenamic acid- 
induced COX-2 expression is at least partly mediated through activation o f MAPKs in 
IEC- 6  cells. TNFa-induced activation o f  NF-kB was suppressed by flufenamic acid or 
sulindac sulfide. However, these NSAIDs did not appear to affect TNFa-induced 
COX-2 expression in IEC- 6  cells. This may be due to two opposing effects: one is
viii
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induction of COX-2 by NSAIDs and the other is induction o f TNFa-induced COX-2 
expression by NSAIDs. The results from these studies provide new insight for 
signaling pathways through which fatty acids and NSAIDs modulate COX-2 and other 
inflammatory marker gene products.
ix




Cyclooxygenase (COX) is the enzyme that catalyzes the conversion of 
arachidonic acid and O2 to prostaglandin endoperoxide H2 (PGH2). COX is also known 
as prostaglandin H synthase. COX has two distinct enzyme activities: 1) a 
cyclooxygenase activity, which catalyzes the conversion o f arachidonic acid to PGG2. 
and 2 ) a peroxidase activity, which catalyzes the conversion o f PGG2 to PGH2 . PGH2 
formed by the action o f  COX is converted via distinct synthases to PGD2, PGE2, PGF2Q, 
PGI2, or thromboxane A 2 (TXA2) [see APPENDIX 1], Non-steroidal anti-inflammatory 
drugs (NSAIDs) compete directly with arachidonate for binding to the cyclooxygenase 
site and inhibit cyclooxygenase activity but have little effect on peroxidase activity 
(Mizuno et al., 1982). Therefore, the cyclooxygenase and peroxidase sites are 
physically and functionally separate. This conclusion is based on results from many 
studies o f protein chemistry, UV-visible spectroscopy, and x-ray crystallography about 
the active sites of COX (Lambeir et al., 1985; Picot et al., 1994; Smith and DeWitt, 
1996).
It has been found that there are two closely related isoforms of COX. which are 
known as COX-1 and COX-2 (Xie et al., 1991; Kujubu et al., 1991; O’Banion et al., 
1991). COX-1 is the constitutive form o f the enzyme and ubiquitously expressed. It 
provides certain homeostatic functions, such as maintaining normal gastric mucosa and 
aiding in blood clotting by abetting platelet aggregation (Simon, 1996).
]
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COX-2 is the inducible form and expressed in response to inflammatory and 
other physiologic stimuli, growth factors, tumor promoters, hormones, bacterial 
endotoxins, and cytokines (DeWitt and Meade, 1993; Evett et al., 1993; Jones et al., 
1993; O’Sullivan et al., 1992). The rapid induction o f COX-2 mRNA, which can be 
superinduced by cycloheximide, parallels the expression o f  c-fos leading to the 
classification o f COX-2 as an immediate early gene (Jones et al., 1993). In fibroblasts, 
increased expression is due to an increased rate of COX-2 gene transcription (DeWitt 
and Meade, 1993). In other systems, post-transcriptional regulation contributes to the 
magnitude and duration o f COX-2 mRNA expression (Ristimaki et al., 1996).
Although both COX-1 and COX-2 convert arachidonic acid to prostaglandins, 
there are many differences between the COX isoforms. One major distinction is that 
COX-2 is the principal isoform that participates in inflammation (Simon, 1999). O f the 
two isoforms, the inducible COX-2 enzyme is thought to make the more important 
contribution to synthesis o f PGs at sites of inflammation as suggested by studies of 
cultured inflammatory cells (Lee et al., 1992) or of synoviocytes from rheumatoid 
arthritis and osteoarthritis patients (Sano et al., 1992). COX-2 expression is inhibited 
by glucocorticoids such as dexamethasone at the level o f  transcription and translation, 
while these agents have little effect on the expression o f  COX-1 (Vane and Botting, 
1995; Masferrer et al., 1994). COX-1 is also not upregulated by inflammatory or other 
stimuli. This leads to a steady state level o f COX-1 that is responsible for the 
production of basal levels o f PGs (Crofford, 1997). Antiinflammatory cytokines, such 
as interleukin-10 (IL-10), can also selectively inhibit COX-2 induction (Mertz et al.,
2
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1994). All of this evidence suggest that COX-2 is responsible for production o f 
prostaglandins involved in inflammation.
Another distinction involves their differential expression. The two isoforms are 
encoded by genes located on separate chromosomes. COX-1 is located on human 
chromosome 9? while COX-2 is located on human chromosome 1 (Funk et al., 1991; 
Jones et al., 1993). Both isoenzymes share 60% genetic homology in their coding 
regions (Smith and DeWitt, 1996). The gene for COX-1 is approximately 22 kilobase 
pairs and contains 11 exons (Kraemer et al., 1992). Typical o f  developmentally 
regulated “housekeeping” genes, the COX-1 gene lacks a TATA box and little is known 
about the details of the regulation o f  COX-1 gene expression. COX-2 is 8  kilobase 
pairs in length and contains 10 exons (Kujubu and Herschman, 1992). The small size o f 
the COX-2 gene is consistent with its characterization as an immediate-early gene 
(Herschman, 1994). The COX-2 promoter contains a TATA box. Several relevant 
enhancer sequences have been identified in the COX-2 gene promoter. In bovine 
endothelial cells, a CEBPp site is responsible for induction o f COX-2 by 
lipopolysaccharides and tumor-promoting phorbol ester while the same site is 
responsible for tumor necrosis factor a-mediated induction o f COX-2 in MC3T3-E1 
cells (Inuoue et al., 1995; Yamamoto et al., 1995). An E-box sequence is essential for 
basal and luteinizing hormone- and gonadotrophin-releasing hormone stimulated 
transcription, and this element binds the upstream stimulating transcription factor 
(Morris and Richards, 1996). A cAMP response element mediates the effect o f src on 
COX-2 expression in fibroblasts (Xie and Herschman, 1995). Transcriptional activation 
o f the COX-2 gene appears to be the major mechanism for increasing COX-2
3
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expression. COX-2 expression can be induced through multiple signaling pathways 
involving protein kinases A and C, tyrosine kinases, phosphatase, bacterial endotoxin, 
and src (Evett et al., 1993; Kester et al., 1994; Smith et al., 1996).
Prostanoid production by COX-1 and COX-2 appears to be initiated through 
distinct signaling pathways that may rely on the activation o f different phospholipases 
(Reddy and Herschman, 1994). In addition, products o f COX-2, but not COX-1, 
localize to the nucleus, which suggests that COX-2 may independently signal to the 
nucleus (Morita et al., 1995).
Although COX-2 is usually barely detectable during normal physiologic 
conditions, there is also some constitutive expression o f this isoform in the rat kidney 
and brain, human prostate and lung, bone, and female reproductive system, (Cryer and 
Dubois, 1998). COX-2 expression also occurs in transformed or cancerous cells. The 
first COX-2 cDNA was initially characterized on the basis o f its elevated expression in 
Rous sarcoma virus transformed chicken embryo fibroblasts (Simmons et al., 1989). 
Constitutive overexpression o f COX-2 has been detected in colon carcinomas (Eberhart 
et al., 1994; Kargman et al., 1995).
Within the cell, both isoforms are located on the endoplasmic reticulum and the 
nuclear envelope (Otto and Smith, 1994). However, the concentration o f  COX-2 within 
the nuclear envelope is approximately twice the concentration in the endoplasmic 
reticulum, while COX-1 is found in equivalent concentrations in both intracellular 
locations (Morita et al., 1995).
The two major substrates for both COX-1 and COX-2 are arachidonic acid and 
dihomo-y-linolenic acid. They are also capable o f  catalyzing the oxygenation o f
4
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
eicosapentaenoic acid (EPA), y-linolenic acid, a-linolenic acid, and linoleic acid 
(Kulmacz et al., 1994; Laneuville et al., 1995). EPA is converted to PGH3, whereas the 
18-carbon fatty acids are converted to monohydroxy acids. There are subtle differences 
in substrate specificities between COX-1 and COX-2. In general, 18-carbon 
polyunsaturated fatty acids are more efficiently oxygenated by COX-2 than by COX-1. 
Docosahexaenoic acid (DHA, 22:6n-3) is a competitive inhibitor o f  both COX-1 and 
COX-2 without being a substrate for either enzyme (Meade et al., 1993).
In enzyme catalysis, COX-1 and COX-2 have similar cyclooxygenase turnover 
numbers (-3500 mol o f arachidonate/min/mol o f dimer), and the Km values for 
arachidonate (-5  pM) and 0 2  (-5 pM) are about the same for both isozymes (Barnett 
et al., 1994). Furthermore, the key residues involved in catalysis are conserved between 
the isozymes, and the crystal structures o f the two isozymes are essentially 
superimposable (Picot et al., 1994). In the overall context of catalytic mechanisms, 
these proteins appear to be essentially the same.
1.2. Prostanoids
Prostaglandins and thromboxanes, collectively known as prostanoids (PGs), are 
produced by biologic oxidation of arachidonic acids. PGs are important mediators of 
inflammation. PGs are synthesized and secreted by a wide variety o f  cells only when 
stimulated by a multitude o f cell perturbations, ranging from mechanical to chemical 
stimuli. Once released, PGs act as autocrine or paracrine factors to regulate the 
functions o f various differentiated cells. The ubiquitous presence o f  PG-metabolizing 
enzymes makes these mediators unstable and their actions short-lived. Due to the short
5
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half-lives o f  PGs in general, the levels and activities of PG synthetic enzymes determine 
the bioactivity o f PGs within tissues (Needleman et al., 1986; Hla et al., 1993)
In arthritis, PGs contribute to synovial inflammation by increasing local blood 
flow and potentiating the effects o f mediators such as bradykinin and interleukin (IL)-l 
that induce increases in vasopermeability (Anderson et al., 1996). PGs also may induce 
osteoclastic bone resorption, suggesting a mechanism through which they may 
contribute to joint erosion (Sano et al., 1992). In patients with inflammatory joint 
disease, there is an increase in synovial and cartilage COX activity (Crofford, 1998).
13 . Lipopolysaccharide (LPS)
Macrophages secrete prostaglandins upon activation by the bacterial endotoxin 
LPS, due to induced transcription o f the COX-2 gene and production o f the COX-2 
enzyme. LPS is a major cell wall component o f Gram-negative bacteria. Activation by 
LPS constitutes the first step in a cascade of events believed to lead to the manifestation 
of Gram-negative sepsis, a condition that results in approximately 20,000 deaths per 
year in the United States (Rietschel and Brade, 1992). Macrophages and monocytes 
respond to LPS by inducing the expression o f cytokines, cell adhesion molecules, and 
low molecular weight proinflammatory molecules. The activation o f monocytes or 
macrophages by LPS requires a serum protein known as LPS-binding protein (LBP) and 
a glycosylphosphatidylinositol-linked cell surface glucoprotein, CD 14 (Wright et al.,
1990). LBP is a 60 kD serum glycoprotein that forms high-affinity stoichiometric 
complexes with LPS. LBP also functions as an opsonin (Rietschel and Brade, 1992). It 
binds to the surface o f bacteria or to LPS-coated erythrocytes and mediates the adhesion 
of these coated particles to macrophages. Interaction o f LPS-LBP complexes with
6
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macrophages subserves not only this adhesive function but also induces the synthesis of 
tumor necrosis factor (TNF) by the macrophages (Wright et al., 1990). CD 14 is a well- 
known marker for monocytes and macrophages. LPS has been shown to initiate 
multiple intracellular signaling events, including the activation o f nuclear factor-kappa 
B (NF-kB), which ultimately leads to the synthesis and release o f a number of 
proinflammatory mediators, including interleukin-1 (IL-l), interleukin- 6  (IL-6 ), 
interleukin- 8  (IL-8 ), and tumor necrosis factor-a (Yamamoto et al., 1995; Cao et al., 
1996). However, CD 14 is not a transmembrane protein and does not have a 
cytoplasmic domain. Therefore, the identity o f a transmembrane protein that could 
relay LPS-induced signals across the cell-surface membrane remained elusive.
Recently, several Toll-like receptors (TLR) have been identified as LPS receptors and 
can interact with CD14 to form the LPS receptor complex (Yang et al., 1998; Yang et 
al., 1999). Toll is a transmembrane receptor in Drosophila involved in dorsal-ventral 
patterning in embryos and in the induction o f an anti-fungal response. The cloning o f a 
family of human receptors structurally related to Drosophila Toll revealed five proteins 
that have extracellular domains containing multiple leucine-rich repeats and 
cytoplasmic domains with sequence homology to the intracellular portion o f the IL-l 
receptor. Recent studies have suggested that TLR2 or TLR4 serves as the main mediator 
o f responses to LPS in vitro and in vivo (Chow et al., 1999; Cario et al., 2000).
LPS treatment leads to receptor oligomerization and to subsequent recruitment 
of IL-lR-associated kinase (IRAK) to the signaling complex, resulting in rapid 
phosphorylation of p42/p44 mitogen-activated protein kinase (MAPK), p38, and c-Jun 
NH2-terminal kinase (JNK) in monocytic cell lines (Reimann et al., 1994; Hambleton,
7
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1996; Han et al., 1997; Kopp et al., 1999; Yang et al., 1999). Downstream LPS 
signaling through TLRs rapidly leads to NF-kB activation in monocytic cells (Zhang et 
al., 1999).
1.4. Mitogen-activated protein kinases (MAPKs)
Eukaryotic cells use a variety o f intracellular signaling pathways to respond to 
changes in their external environment. Among these pathways, the MAPK cascade is a 
major signaling system by which cells transduce extracellular signal into intracellular 
responses (Waskiewicz and Cooper, 1995; Treisman, 1996). Many steps o f this cascade 
are conserved during evolution. Thus, MAPKs might play an essential role in diverse 
intracellular signaling processes from yeast to mammalian cells (Nishida and Gotoh,
1993; Marshall, 1994). MAPKs were originally described as serine/threonine kinases 
that are activated commonly by various growth factors and tumor promoters in 
mammalian cultured cells (Ray and Sturgill, 1987; Hoshi et al., 1988). They are now 
thought to function as key molecules in signaling processes stimulated by the growth 
factors, cytokines, hormones and differentiating factors and also in the M phase cascade 
reactions downstream o f maturation promoting factor (MPF) (Cobb et al., 1991; Gotoh 
etal., 1991; Ferrell, e ta l., 1991; Posada et al., 1991).
MAPKs are activated by dual threonine/tyrosine phosphorylation o f residues in 
the activation loop catalyzed by a specific MAPK kinase (MEK). The MEK is 
activated by Ser/Thr protein kinase, the MAPK kinase kinase (MEKK), which 
phosphorylates two serine or threonine residues within a Ser-X-X-X-Ser/Thr motif. In 
general, the MEKK -»■ MEK -*■ MAPK cascade functions as a module. There are 
multiple MAPK modules in mammalian cells. At present, three main classes of
8
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MAPKs pathways are recognized. They are the extracellular signal-regulated kinases 
(the ERKs) pathway, the c-Jun N-terminal kinases/stress-activated protein kinases (the 
JNK/SAPK) pathway, and the p38/HOG pathway (Davis, 1993; Davis, 1994; Cano and 
Mahadevan, 1995; Cobb and Goldsmith, 1995). Each pathway is a 3-kinase cascade 
consisting of a MAPK, which is activated by a MEK that in turn is activated by a 
MEKK.
The ERKs pathway consists o f Raf-1, MEK-1 (or MEK-2), and ERK-1 (or 
ERK-2). This pathway can be activated by various extracellular stimuli including 
phorbol esters and growth factors, such as epidermal growth factor (EGF) and platelet- 
derived growth factor (PDGF). ERK-1 (also known as MAPK-1) and ERK-2(also 
known as MAPK-2) were the first two members o f the MAPK subfamily to be purified 
and cloned (Boulton et al., 1991; Davis, 1993). They are the best-characterized MAPKs 
so far in terms of the signaling pathway involved in their activation and the 
identification o f physiological targets. They are 44-and 42-kd enzymes that display 90 
% amino acid identity in the protein kinase catalytic core and 83 % identity overall 
(Cobb et al., 1994). Other closely related enzymes include ERK-3, ERK-4, and ERK-5 
(Gonzalez et al., 1992; Boulton et al., 1991; Zhou et al., 1995). The activation of 
ERKs pathway can be initiated through activation o f transmembrane receptors with 
intrinsic or associated protein tyrosine kinase (PTK) activity through binding of 
extracellular ligands to their receptors. After the association o f autophosphorylated 
receptor and adaptor protein such as growth factor receptor-bound protein 2 (Grb2), 
Grb2 binds to the guanine nucleotide-exchange protein SOS which, in turn, increases 
the association of Ras with GTP. The GTP-bound form o f Ras interacts with the protein
9
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kinase Raf-1 (MEKK). Then, MEK-1 or MEK-2 is phosphorylated and activated by 
Raf-1. MEKs phosphorylate and activate the ERKs. Activated ERK translocates into 
the nucleus and phosphorylates other protein kinases (e.g. Rsk) and transcription factors 
(e.g. Elk-1, NF-IL6 ).
The JNK/SAPK pathway consists of MEKK—1, MEK-4, and JNKs/SAPKs. The 
JNK/SAPK pathway is potently and preferentially activated by cellular stresses such as 
heat shock, recovery from protein synthesis inhibition. ATP depletion, UV radiation, 
and by inflammatory cytokines such as TNFa and IL-l p (Kyriakis et al., 1994; Derijard 
et al., 1994). In this pathway, GTP-bound forms o f the small GTP-binding proteins such 
as Rac or Cdc42 activate p21-activated kinase (PAK), which activate MEKK-1. Then, 
activation of MEK-4 by MEKK-1 leads to activation o f  JNK/SAPK, which include 
JNK-1 (p45 SAPK a /p )  and JNK-2 (p54 SAPK a/p/y) (Lin, et al., 1995; Gupta et al.,
1996). The JNK/SAPK stimulates c-Jun transcriptional activity, by phosphorylation of 
residues Ser 63 and Ser73 in c-Jun’s activation domain (Pulverer et al., 1991; Smeal et 
al., 1991). JNKs also appear to be responsible for activation of transcription factor, 
ATF2. Phosphorylation o f c-Jun and ATF2 increases their transcriptional activity, 
leading to enhanced c-Jun transcription followed by increased c-Jun synthesis. The 
newly synthesized c-Jun may combine with c-Fos or ATF2, or form homodimers, all of 
which can contribute to increased AP-1 activity (Karin and Hunter, 1995).
The p38/HOG pathway consists o f MEKK-1, MEK-3, and p38/HOG. This 
pathway is activated by various extracellular stimuli including LPS, heat, chemical 
stress, high osmolarity, ultraviolet light, and inflammatory cytokines (Han et al., 1994; 
Robinson and Cobb, 1997). Waskiewicz and Cooper (1995) reported a negative role for
10
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p38 in cell proliferation. Its activation inhibited transcription o f cyclin D l. and should 
therefore inhibit cell cycle progression (Lavoie et al., 1996). p38 is a vertebrate 
homolog o f the yeast HOG gene (Han et al., 1994). There are several isoforms: p38a, 
p38p, p38y, and p385 ( Jiang et al., 1996; Jiang et al., 1997; Li et al., 1996). Like its 
homolog HOG, p38 is activated by phosphorylation on both threonine and tyrosine.
Two p38 activators have been characterized: SEK.1 (also the activator o f JNK.) and 
MEK3 (specific for p38) (Lin et al., 1995). The known downstream targets o f p38 are 
a seryl/threonyl kinase, MAPK-activated protein kinase (MAPKAPK) 2, and the 
transcription factor ATF-2 (Rouse et al., 1994).
1.5. Nuclear factor kappa B (NF-kB)
N F-kB is a eucaryotic transcription factor that exists in virtually all cell types. It 
was first identified in 1986 as a nuclear factor necessary for immunoglobulin kappa 
light chain transcription in B cells (Sen and Baltimore, 1986). It was originally thought 
that N F -kB was not produced in other cells. It is now known that N F-kB preexists in 
the cytoplasm o f most cells in an inactive form bound to the inhibitor, IkB (Baeuerle 
and Baltimore, 1988). Upon receipt o f  an appropriate signal, N F-kB is released from 
IkB and translocates to the nucleus where it can upregulate transcription o f specific 
genes. Since N F-kB activity does not require new protein synthesis, the signal is 
transmitted quickly. Upon appropriate cellular stimulation, IkBs are specifically 
phosphorylated and degraded through a ubiquitin/proteasome-dependent mechanism 
(Ghosh et al., 1998). The kinases responsible for phosphorylating IkB are known as the 
IkB kinases, IKK-1 and IKK-2, and they form a large multiprotein complex that 
contains scaffolding proteins such as IKAP and NEMO (IKKy) (Cohen et al., 1998;
11
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Rothwarf et al., 1998; Yamaoka et al., 1998; May and Ghosh, 1998). The IKKs are 
believed to be activated through phophorylation by a kinase belonging to the MAP 
kinase kinase kinase (MAPKKK) family. Those kinases include NIK (NF-kB inducing 
kinase) and MEKK-1 (mitogen-activated protein kinase/ERK kinase kinase-1) and they 
can activate NF-kB through phosphorylation and activation o f the IKKs. TRAF6  is 
capable of binding NIK and may therefore activate NF-kB via a NIK-IKK pathway 
(Kopp et al., 1999). TRAF6  is a member o f the TRAF family o f  adaptor proteins. The 
TRAFs (TNF-receptor associated factors) were first described as proteins that are 
recruited to the tumor necrosis factor (TNF) receptors during signaling (Rothe et al.,
1994). There are currently six TRAF proteins known. TRAF 1 -5 are recruited to the 
TNF receptor complex and activate N F -kB via the kinase RIP (Receptor Interacting 
Protein), whereas TRAF6  participates in IL-l receptor and Toll activation o f NF-kB by 
interacting with the kinase IRAK (Cao et al., 1996; Arch et al., 1998).
1.6. Dietary fatty acids 
The dietary lipids that have nutritional value are in the form o f triglycerides, or 
neutral fat. Triglycerides are composed o f two parts, glycerol and fatty acids, the fatty 
acids being esterified to the three hydroxyl groups o f  the glycerol. Fatty acids are either 
saturated or unsaturated. Unsaturated fatty acids contain one or more double bonds. 
Those which have one unsaturated bond are monounsaturated fatty acids and those 
which have two or more unsaturated bonds are polyunsaturated fatty acids (PUFAs). 
PUFAs are usually classified according to a shorthand nomenclature which designates 
the chain length, number of double bonds, and position of the double bond nearest to 
the terminal methyl group (Willis, 1987). The carbon atom o f the methyl terminal end
12
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is referred to as the n carbon atom, as it occurs at the opposite end o f the molecule to 
carbon-1 o f the carboxyl group. The to can be used instead of n to describe the position 
of the double bond nearest the methyl group. There are four families o f unsaturated 
fatty acids: n-3, linolenic acid (LNA, C18:3n-3); n-6 , linoleic acid (LA, C18:2n-6); n-7, 
palmitoleic acid (C l6:1 n-7); and n-9, oleic acid (OA, C18:ln-9) (Cave, 1991). The n-3 
and n- 6  polyunsaturated fatty acids are considered essential fatty acids (EFA) because 
they cannot be synthesized by the human body and must be obtained from the diet.
They have distinctive nutritional and metabolic effects, and each has a direct precursor 
relationship with specific classes o f eicosanoids. Thus, all eicosanoids formed in the 
human body are generated from polyunsaturated fatty acids that must be derived from 
the diet (Fischer, 1989). Oleic acid is not an essential fatty acid because animals 
possess desaturase and so can synthesize the n-9 fatty acids by chain elongation and 
desaturation.
Most human diets contain a variety o f saturated fatty acids o f different chain 
lengths. The major saturated fatty acid in the diet is palmitic acid (PA, C l6:0), 
followed by stearic acid (SA, C18:0), myristic acid (C14:0), and lauric acid (0 2 :0 ) . 
Short and medium chain fatty acids (C4:0-10:0), which occur mainly in dairy fat, palm 
kernel oils and coconut oils, also contribute to the total intake of saturated fatty acids 
(Bartsch et al., 1999). PA is found in all edible fats and oils and is particularly abundant 
in palm oil and in butter, milk, cheese and meats. SA is found predominantly in cocoa 
butter and in fats from cattle and sheep. Coconut and palm kernel oils, and dairy fats 
contain large amounts o f lauric and myristic acids. The major monounsaturated fatty 
acid in human diets is oleic acid (OA, cis-C 18:1 n-9). OA is found in all edible fats and
13
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oils and is particularly abundant in olive and rapeseed oils. The major polyunsaturated 
fatty acid in the diet is linoleic acid (cis,cis-C18:2n-6). LA is present in vegetable oils 
such as those from soybeans, com and sunflowers (Ip, 1997). Linolenic acid (n-3) is 
present in dark green leafy vegetables, walnuts, and in linseed and rapeseed oil. The n-3 
fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are 
present in fish (Bartsch et al., 1999).
The n-3 fatty acids are derived from LNA while the n-6 fatty acids are derived 
from LA (Figure 1). The LA and arachidonic acid (AA) are representative of the n-6 
fatty acid while LNA, EPA, and DHA represent n-3 fatty acids. AA and EPA are 
precursors to eicosanoids such as PG and leukotrienes. EPA and AA are known to 
compete for the enzymes that metabolize these PGs and leukotrienes (Culp et al., 1979). 
Thus, the ratio o f n-3:n-6 EFA may be an important factor in the type o f PG or 
leukotrienes synthesized.
1.7. Cancer and dietary fatty acids
Wynder and Gori (1977) and Doll and Peto (1981) reported that about 35% 
(range 10-70%) o f all cancer mortality in the United States may be attributable to 
dietary factors. Epidemiological studies have demonstrated that diets particularly high 
in fish and other marine animals are generally associated with a reduced risk for the 
development o f  several types o f cancer (Mckeown-Essen and Bright-See, 1985; Rose et 
al., 1986).
Colon cancer rates are lower in countries where consumption o f fish oils is high, 
such as Japan (Lands et al., 1990). Kromann and Green (1980) reported a lowered
14
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Figure 1.1. Outline of three major groups of dietary fatty acids metabolism 
(Hwang, 1989).
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incidence of cancers in general among Greenland Eskimos who consume large amounts 
o f seal and fish oil rich in the n-3 PUFAs.
Many epidemiological studies have shown that even though the overall fat 
consumption is high, the incidences of cancers are different depending on the primary 
fatty acids consumed (Hursting et al., 1990; Sasaki et al., 1993; Wynder et al., 1991). 
These differences in cancer incidence might come from differences in the ratio o f n-6/n- 
3 PUFAs in the diet. Therefore, the ratio of n-6/n-3 PUFAs in the diets might be an 
important factor in determining cancer risk. Although an optimal ratio o f n-6/n-3 fatty 
acids has yet to be determined, Bartsch et al. (1999) recommend a ratio o f 8:1 —5:1 (n- 
6/n-3).
Calder et al. (1998) reported that dietary fish oil suppresses human colon tumor 
growth in athymic mice. They found that; 1) human colon tumor growth is promoted by 
feeding high fat diets rich in medium chain saturated fatty acids or monounsaturated 
fatty acids, 2) a high fat diet, rich in long chain n-3 PUFAs does not promote colon 
tumor growth, 3) the effect o f a high fat diet rich in n-6 PUFAs depends upon the timing 
o f feeding: if fed before tumor cell inoculation, this diet promotes tumor growth, but if 
fed once tumor growth is initiated, there is no growth promoting effect, 4) therefore, n-6 
PUFAs might affect initiation o f colon tumor growth, but not promotion.
Karmali et al. (1987) showed that feeding menhaden oil or n-3 fatty acid-rich 
fish oil concentrate suppresses the growth of human prostate cancer cells after their 
subcutaneous injection into athymic nude mice. They suggested that this inhibitory 
effect was associated with a reduction in tumor prostaglandin E2-
16
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Fay et al. (1997) reported the effects o f saturated and monounsaturated fats and 
n-6 PUFAs and n-3 PUFAs on mammary tumor incidence. The results indicated that n- 
6 PUFAs have a strong and saturated fats a weaker tumor-enhancing effect, whereas the 
n-3 PUFAs have a small, statistically nonsignificant protective effect and 
monounsaturated fats had no significant effect. Willett et al. (1990) reported that there 
appears to be no correlation between the incidence o f colon cancer and total intake o f n- 
6 PUFAs.
Recent studies that focused on the effects o f n-3 and n-6 PUFAs on tumor 
metastases showed conflicting results, n-3 PUFA diets either reduced or increased the 
number o f  metastases or had no effect at all (Rose and Connolly, 1993). Suzuki et al. 
(1997) showed the inhibitory effects o f n-3 fatty acids on lung metastasis. Young and 
Young (1989) found that n-3 PUFAs can increase the number o f lung metastasis. 
Griffini et al. (1998) reported that both n-3 and n-6 PUFAs promote colon cancer 
metastasis in rat liver without down-regulating the immune system.
Taken together, there is now substantial experimental evidence that in general n-6 
fatty acids increase the risks for cancers o f the breast and colon and for metastasis, 
whereas relatively high intakes o f n-3 PUFAs and n-9 monounsaturated fatty acids 
reduce cancer risk by mechanisms that may involve modification o f the biosynthesis of 
eicosanoids from n-6 PUFAs.
1.8. Fatty acids and immune response 
Epidemiological study demonstrated low incidence o f atherosclerosis, and 
inflammatory and autoimmune diseases in Greenland Eskimos who consume diets 
enriched in marine-derived (n-3) PUFAs (Kromann, 1980). Recent clinical studies with
17
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fish oil supplemented diets have shown that fish oil diets might be beneficial for the 
prevention and treatment o f atherosclerotic and atherothrombotic disorders and may 
improve autoimmune and inflammatory diseases (Gottschlich, 1992; Meydani and 
Dinarello, 1993; Meydani et al., 1993; Goodnight, 1996). Kremer et al. (1987) 
suggested that several diseases including atherosclerosis, insulin-resistant diabetes, and 
certain types o f  cancer such as colon cancer have been linked to the type and amount of 
fat we ingest. They showed that rheumatoid arthritis patients consuming 1.8 g/d o f EPA 
had fewer clinical symptoms after 12 weeks of supplementation. Renier et al. (1993) 
showed that fish oil-induced reduction of IL-1P and TNF-a production in mice was 
associated with reduced atherosclerotic lesions. Cytokines such as IL-1 have been 
shown to contribute to the pathogenesis of atherosclerotic and inflammatory diseases. 
Therefore, an increase in n-3 PUFAs intake can be expected to affect cytokine 
production and biologic function (Meydani, 1996).
Meydani et al (1991) showed that fish oil consumption significantly decreased T 
cell-mediated function such as IL-2 production and mitogenic response to T cell 
mitogen PHA in a human study. Somers et al (1989) reported that dietary 
manipulation o f  fatty acids can alter activation o f tumoricidal capacity of macrophages, 
possibly through the changes in eicosanoid synthesis.
Recent studies indicate that signal transduction and subsequent gene expression 
can be modified by n-3 fatty acids. Erickson et al. (1995) reported that dietary fatty 
acids might modulate signal transduction in mice macrophages. They suggested that 
effects o f dietary fatty acids on macrophages might be a combination o f several 
mechanisms and modulation o f a more complicated set o f events. Lo et al. (1999)
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reported that EPA-supplemented diets decrease macrophage tumor necrosis factor gene 
transcription by altering NF-tcB activation by reducing the p65/p50 dimers. May et 
al.(1993) showed that lymphocyte protein kinase C is inhibited by unsaturated fatty 
acids.
Moreover, EPA and DHA are incorporated into the cell membrane, where they 
influence membrane fluidity, receptor function, enzyme activity, and production of 
eicosanoids (Brouard and Pascaud, 1990).
Therefore, dietary fatty acids appear to influence the onset and progression o f 
these various diseases by exerting an effect at two levels: (1) changes in membrane 
phospholipid composition; and (2) direct control of the nuclear events that govern gene 
transcription (Clandinin et al., 1991; Clarke and Abraham, 1992). Therefore, the 
beneficial as well as the detrimental effects that dietary fats exert on various diseases 
may involve a combination o f interactive regulatory mechanisms: (1) rapid changes in 
gene expression and (2) a long term adaptive modulation of membrane composition, 
which leads to changes in hormone signaling (Clarke and Jump, 1994).
1.9. Non-steroidal anti-inflammatory drugs (NSAIDs)
By the early 1900s, the main therapeutic actions o f Aspirin (and sodium 
salicylate itself) were known as the antipyretic, anti-inflammatory, and analgesic effects 
(Vane, et al., 1990). In time, several other drugs were discovered that had some or all 
of these effects; these drugs include antipyrine, phenacetin, acetaminophen, fenamates, 
indomethacin, and naproxen. Because of their similar therapeutic actions, these drugs 
tended to be regarded as a group and were generally known as the ‘Aspirin-like drugs’; 
because they were clearly distinct from the glucocorticoids, the other major group o f
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agents used in the treatment o f inflammation, these drugs were considered the ‘non­
steroidal anti-inflammatory drugs (NSAIDs)' (Flower, 1974). Although the drugs in 
this group are chemically diverse, the fact that most o f them possess an acidic function 
suggested another name that is still occasionally encountered-the ‘anti-inflammatory 
acid’.
Despite the diversity o f their chemical structures, these drugs share to some 
extent the same therapeutic properties. In varying doses, they alleviate the swelling, 
redness, and pain o f inflammation, reduce a general fever, and cure a headache. In 
addition, they also share, to varying degrees, many similar side effects. Depending on 
the dose, these drugs can cause gastric upset; a high dose can delay the birth process; 
and an overdose may damage the kidneys. A particularly interesting side effect, which 
is now known as a therapeutic action, is their antithrombotic effect.
In 1971, Vane reported that aspirin and indomethacin inhibit the biosynthesis of 
prostaglandins in the guinea pig lung. In 1974, [acetyl-3 H] aspirin was shown to 
selectively acetylate a microsomal protein o f molecular weight 85,000 (now known as 
COX-1) from a sheep and bull seminal vesicles and human platelets (Roth et al., 1975). 
In 1980s, numerous enzymatic studies were reported that defined the nature o f the 
interactions of various NSAIDs with purified COX-1 (Smith and DeWitt, 1995). It was 
shown that only the cyclooxygenase activity of COX-1, but not the peroxidase activity 
o f  COX-1, was blocked by NSAIDs (Mizuno et al., 1982).
Soon after the discovery that COX-2 was the enzyme responsible for 
inflammatory responses, the effects of various NSAIDs on COX-2 were scrutinized and 
compared with those on COX-1 (Meade et al., 1993). On the basis of their binding
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kinetics with the COXs, NSAIDs can be grouped into three classes. Class I compounds 
are simple, competitive inhibitors that compete reversibly with arachidonic acid for 
binding to the COX active site, whereas class II compounds are competitive, time- 
dependent, and reversible inhibitors. Class III compounds are known to covalently 
modify COX-1 and COX-2 and include aspirin. Acetylation of COX-1 by aspirin 
inactivates the COX activity, but not its peroxidase activity. Aspirin acetylation of 
COX-1 prevents arachidonic acid from getting contact with the active site (DeWitt et 
al., 1990). The active site o f COX-2 is slightly larger than that o f COX-1 (Lecomte, et 
al., 1994). This size difference is suggested by the broader fatty acid substrate 
specificity o f COX-2 and the lower relative affinities o f NSAIDs for COX-2 (Smith and 
DeWitt, 1995). Most NSAIDs inhibit the activity o f both COX-1 and COX-2, a 
property that accounts for their shared therapeutic and side effects (Vane, 1971). The 
inhibition o f COX-2 may well explain their therapeutic use as anti-inflammatory drugs, 
whereas the inhibition of COX-1 may explain their unwanted side effects, such as 
gastric damage (Vane, 1971).
Although NSAIDs act principally by inhibition o f  COX, thus blocking the initial 
step in prostanoid synthesis, they appear to possess additional pharmacological actions. 
Low doses o f aspirin and other NSAIDs are enough for COX inhibition in vitro and in 
vivo, whereas higher doses are required for antirheumatic effects in vivo (Roth et al., 
1983).
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CHAPTER2 
THE EFFECT OF DIETARY FATTY ACIDS ON CYCLOOXYGENASE-2 
EXPRESSION
2.1. Introduction
During the past two decades, epidemiological studies have shown a causal 
relationship between the environment and lifestyles of people and the incidence and 
morbidity o f certain diseases, including certain types of cancers. Although it is 
difficult to assign the exact proportion o f these diseases attributable to dietary factors 
alone, Wynder and Gori (1977) estimated that 35 % (range 10-70 %) o f cancer 
mortality in the United States is from dietary factors. Much evidence from both 
epidemiological and experimental studies supports a positive association between 
consumption o f fish and marine animals and a reduction in the risk for development o f 
several types o f cancer and some autoimmune diseases (Kremer et al., 1987; Kromann 
and Green, 1980; Miller, 1990; Rose, 1997).
Many epidemiological studies suggest that the intake o f fish containing n-3 
polyunsaturated fatty acids (PUFAs), mainly docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA), is associated with a reduced risk o f colon cancer 
(Giovannucci and Goldin, 1997; Potter, 1995; Reddy, 1994). Furthermore, 
administration o f EPA in the diet has been shown to reduce carcinogen-induced rat 
colon carcinogenesis (Minoura et al., 1988). Takanashi et al. (1993 andl997) found 
DHA can suppress carcinogen-induced rat colon carcinoma development. Oshima et al. 
(1995) also showed that DHA suppresses intestinal polyp development in APC 
knockout mice.
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n-3 PUFAs interfere with the metabolic pathway of arachidonic acid and thereby 
decrease prostaglandin E2 levels (Corey et al.. 1983). Thus, it has been postulated that 
the anti-cancer effect of n-3 PUFAs is due to their inhibitory effect on prostaglandin 
biosynthesis from arachidonic acid. However, the molecular mechanisms by which n-3 
PUFAs exhibit their anti-carcinogenic effects have yet to be fully understood.
Several studies suggested that anti-inflammatory effects of dietary fatty acids 
might occur by modulating the macrophage intracellular signal pathways which, in turn, 
influence gene activation and cytokines production (Meydani and Dinarello, 1993; Lo et 
al., 1999). Prostaglandin E2 (PGE2) is one o f  the major arachidonic acid metabolites 
involved in the modulation of inflammatory response. Prostaglandins are formed by the 
action of cyclooxygenase (COX). COX, also known as prostaglandin endoperoxide H 
synthase, is the rate-limiting enzyme which catalyzes the conversion o f  arachidonic acid 
to prostaglandin H2. There are two isoforms o f  COX so far identified: constitutively 
expressed COX-1 and mitogen-inducible COX-2. The COX-2 gene is overexpressed 
in several proliferative pathological conditions such as cancer and rheumatoid arthritis 
(Sano et al., 1995). COX-2 is induced by endotoxin and inflammation. COX-2 is 
responsible for increased PGE2 in inflamed tissues. COX-2 gene activation is also 
responsible for the elevated PGE2 production by LPS-stimulated macrophages (Lo et 
al., 1998).
It is believed that one possible mechanism for the anti-inflammatory effects of 
PUFAs may be the inhibition of COX-2 and prostaglandin synthesis. This is supported 
by a study that showed the inhibitory effect o f PUFAs on cytokine production (Meydani 
et al., 1993). Lo et al. (1998) suggested that COX-2 gene expression by LPS-stimulated
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macrophages is dependent on nuclear factor kappa B (NF-kB). NF-kB is a 
transcriptional activator protein and plays an important role in controlling inflammatory 
gene activation. NF-kBs are composed o f dimers that are normally confined in the 
cytoplasm through their association with the inhibitory protein, IkBoc. The schematic 
illustration o f LPS signaling pathway leading to the expression of COX-2 is shown in 
scheme 1. A specific DNA sequence recognized by NF-kB transcription factor is 
present in the promoter regions of COX-2 gene.
Recent studies showed that fatty acids are ligands for peroxisome proliferator 
activated receptors (PPARs), suggesting that they are potential modulators for gene 
expression. PPARs are members o f the steroid hormone receptor superfamily which 
regulate gene expression by binding to a recognition sequence known as a PPAR 
response element (PPRE). So far, three subtypes (a , p/5 and y) have been identified. 
Transcriptional regulation by PPARs is achieved through PPAR-RXR (where RXR is 
the receptor for 9-cis retinoic acid) heterodimers. Recently, Meade et al. (1999) 
demonstrated that fatty acids as PPARs activators can induce COX-2 expression in the 
epithelial cells, and COX-2 promoter region has PPRE sequence. Staels et al. (1998) 
reported that PPARa activator can inhibit the expression o f a variety o f genes involved 
in the inflammatory response, including COX-2, in smooth muscle cells. They 
concluded that this inhibition of COX-2 induction occurs transcriptionally as a result o f 
PPARa repression o f  NF-kB signaling.
It has been observed that dietary n-3 PUFAs can relieve the symptoms of 
rheumatoid arthritis and this is associated with decreased PGE2 synthesis. However, the
24
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Scheme 1. The schematic illustration of signaling pathways leading to expression 
of COX-2.
25
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
molecular basis on the regulation o f anti-inflammatory response by dietary fatty acids is 
very poorly understood. Therefore, in this study, it was hypothesized that dietary fatty 
acids may modulate the inflammatory response by influencing the COX-2 signaling 
pathway. The purpose o f this study is (1) to examine the effects o f several dietary fatty 
acids on COX-2 gene expression in a macrophage cell line and, (2) to investigate the 
signaling pathway through which fatty acids modulate COX-2 expression in RAW
264.7 cells. Results from the present study will provide a plausible mechanism of 
PUFAs on the anti-inflammatory response in macrophages.
2.2. Materials and methods
2.2.1. Materials
Docosahexaenoic acid (22:6n-3; DHA), eicosapentaenoic acid (20:5n-3; EPA), 
arachidonic acid (20:4n-6; AA), linoleic acid (18:2n-6; LA), palmitic acid (16:0; PA) 
and stearic acid (18:0; SA) were purchased from Nu-Chek (Eslyan, MN). Rumenic acid 
[9 (Z), 11 (E) -octadecadienoic acid; conjugated linoleic acid (cLA)] was purchased 
from Matreya (Pleasant Gap, PA). Lipopolysaccharide (LPS) was purchased from 
DIFCO (Detroit, Michigan). Antibodies for iNOS, IL -la , and IicBa were purchased 
from Santa Cruz Biotech (Santa Cruz, CA). Donkey anti-rabbit and goat anti-mouse 
immunoglobulin G (IgG) antibodies conjugated to horseradish peroxidase were 
purchased from Amersham Pharmacia Biotech (Arlington Heights, IL). Enhanced 
chemiluminescence (ECL) western blotting detection reagents were purchased from 
Amersham Corp (Piscataway, NJ). SuperFect Transfection Reagent was purchased 
from Qiagen (Valencia, CA). Luciferase Assay System and P-galactosidase Enzyme 
System were purchased from Promega (Madison, WI). Phoenix amphotropic cells were
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provided by Dr. G. P. Nolan (Department o f Molecular Pharmacology and 
Microbiology and immunology, Standford University School o f  Medicine, Standford, 
CA). MTT (3-{4,5-Dimethylthiazol-2-yI}-2,5-diphenyltetrazoliumbromide) and bovine 
serum albumin were purchased from Sigma (St Louis, MO). All other reagents were 
purchased from Sigma unless otherwise described.
2.2.2. Cell culture
RAW 264.7 cells (a murine macrophage-like cell line. ATCC TIB-71) and 
HT29 (a human colon adenocarcinoma cell line, ATCC HTB-38) were cultured in 
Dulbecco’s Modified Eagle's Medium (DMEM, GIBCO-BRL) containing 10% (v/v) 
heat-inactivated fetal bovine serum (FBS, Intergen) and 100 units/ml penicillin and 100 
pg/ml streptomycin (GIBCO-BRL) in a 5% C02/95% air humidified atmosphere at 
37°C. IEC-6 cells (rat normal small intestine cell line, ATCC CRL-1592) were cultured 
in DMEM containing 5% FBS, 0.1 U/ml o f insulin, 100 units/ml penicillin and 100 
pg/ml streptomycin. Media were changed every other day.
2.2.3. Nude mice studies
Female athymic nude mice (NCr-nu/nu) were purchased from Harlen Sprague 
Dawley, Inc. (Indianapolis, Indiana) at three to four weeks o f age and maintained in 
microisolator cages within a pathogen-free isolation facility. There were 8 mice in each 
group. Mice were housed four animals per cage. Mice were injected with 2 x 106 IEC-6 
cells (200 pi of cell suspension) subcutaneously using a 25 gauge needle. The 
experiment was terminated 21 days after injection o f the cells.
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2.2.4. Preparation of fatty acids-albumin complexes
All fatty acids were solubilized in ethanol. They were combined with fatty acid 
free albumin at a molar ratio o f 10:1 (fatty acid : albumin) in serum poor medium 
(0.25% FBS). Fatty acids-albumin complexes solution was freshly prepared prior to 
each experiment. The final concentration o f DHA, EPA, and AA was from 5 to 200 
p.M. LA, cLA, PA, and SA were tested from 1 to 200 pM. This concentration was 
found not to be toxic to the cells.
2.2.5. Preparation of whole cell lysates
After treatment, cell medium were removed and cells were rinsed with cold PBS 
twice. Then 0.5 ml o f ice cold RIPA buffer [see APPENDIX 4] were added to 60 mm 
cell culture dishes. After 20 min incubation on ice, cells were collected by scraping the 
dishes with a cell scraper and transferred to 1.5 ml microcentrifuge tube. After 
sonification (7 strokes x 5), cell lysates were centrifuged at 10,000xg for 10 min at 4 °C. 
The supernatant fluid is whole cell lysates. The protein concentration was measured 
using Bio-Rad protein assay reagents (Bio-Rad Laboratories, Richmond, CA).
2.2.6. SDS-PAGE and western blotting
Whole cell lysates were boiled for 5 min and electrophoretically resolved on a 
8% polyacrylamide vertical slab gel [see APPENDIX 4] with an overlay o f 4% 
polyacrylamide gel along with prestained SDS-PAGE molecular weight markers 
(Biorad). Electrophoretically resolved proteins were electrotransfered onto PVDF 
membrane in a electrophoretic transfer cell (Biorad) containing transfer buffer [see 
APPENDIX 4]. After transblotting the electrophoretically resolved proteins, the blots 
were blocked with 5% (w/v) nonfat dry milk (NFDM, Carnation) dissolved in
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phosphate buffered saline-0.1 % (v/v) Tween 20 (PBS-T) for overnight at 4°C to 
prevent non-specific binding o f  antibodies. The blots were then incubated with 
polyclonal anti-COX-2 antibody diluted 1:5000 in PBS-T containing 5% (w/v) NFDM 
for 1 hour. Blots were washed in PBS-T and reincubated with antirabbit IgG coupled to 
horseradish peroxidase diluted 1:5000 in PBS-T containing 5% (w/v) NFDM. The blots 
were thoroughly washed in excess PBS-T and probed with the enhanced 
chemiluminescence (ECL) western blot detection system (Amersham Corp.). The blots 
were exposed on an X-ray film (Kodak) and the films were developed.
For GAPDH immunoblotting, membranes used for COX-2 immunoblots were 
stripped in the stripping buffer [see Appendix] at 54 °C for 1 hour, reprobed with 
1:10,000 dilution o f GAPDH antibody, and followed by incubation with anti-rabbit IgG 
coupled to horseradish peroxidase diluted 1:5000 in PBS-T containing 5% (w/v) 
NFDM. The blots were thoroughly washed in excess PBS-T and probed with the 
enhanced chemiluminescence (ECL) western blot detection system (Amersham Corp.). 
The blots were exposed on an X-ray film (Kodak) and the films were developed.
2.2.7. Antiphosphotyrosine immunoblotting
12 % o f polyacrylamide gel was used for electrophoresis. Immunoblotting was 
carried out using 4G10 monoclonal antiphosphotyrosine antibody (Upstate 
Biotechnology, Lake Placid, NY) diluted 1:3000 in TBS-0.1 % (v/v) Tween 20 (TBS-T) 
containing 5% (w/v) bovine serum albumin (BSA) followed by incubation with anti­
mouse IgG coupled to horseradish peroxidase diluted 1:5000 in TBS-T.
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2.2.8. Immunoprecipitation
500ug o f whole cell lysates were used for COX-1 and COX-2 
immunoprecipitation. Whole cell lysates were incubated with 2 pi o f antibody for 3 
hours at 4°C on a rotating device and reincubated for 3 hours after adding 80 pi of 20 % 
(v/v) protein A-sepharose beads. The pellet was collected by centrifugation at 10,000xg 
for 10 min at 4°C. The pellet was washed 3 times with RIPA buffer, each time 
repeating the centrifugation step above. After the final wash, the pellet was resuspended 
in 60 pi o f 2x Laemmli buffer [see APPENDIX 4] and boiled at 100°C for 5 min. The 
denatured samples were centrifuged at 10,000xg for 5 min at 4 °C and only the 
supernatant was used for SDS-PAGE.
2.2.9. Transfection and infection
Phoenix cells (lxlO6 cells) were plated into a 60 mm dish one day before 
transfection. To prepare DNA/Superfect reagent complexes, 5 pg o f DNA was diluted 
with DMEM incomplete media in an eppendorf tube. Superfect reagent (30pl) was 
added to the same tube. The DNA/SuperFect reagent complexes were incubated for 10 
minutes at room temperature. Then, 1 ml of complete media was added to the reaction 
tube. After several pipettings, the complexes were added to the phoenix cells. After 3 
hours incubation, the media were removed and changed with DMEM complete media. 
After 24 hours post transfection, the culture media containing infectious viral particles 
produced by transfected phoenix cells were transferred to 15 ml culture tubes and 
centrifuged at 1,500 rpm for 5 minutes at room temperature. Only the supernatant was 
added to infect cells. Polybrene was added to increase the efficiency o f infection. After
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24 hours postinfection, the culture media was removed and changed with complete 
media.
2.2.10. Radioimmunoassay
The cell culture media were removed and collected for measuring accumulated 
prostaglandin E2 . The cells were further incubated in the fresh medium containing 
arachidonic acid (30pm) for 10 min to determine COX activity. After 10 minutes 
incubation, the media were collected in sample vials. Levels of prostaglandin E2 in cell 
supernatants were determined by radioimmunoassay as an indication o f COX enzyme 
activity.
2.2.11. Luciferase reporter gene assay
RAW 264.7 cells were plated in 6 well plates (5 x 105 cells/well) and transiently 
transfected with lp g  o f reporter plasmid and 0.5 pg o f HSP70-lacZ as an internal 
control by using SuperFect transfection reagent (Quiagen, Valencia, CA). After 
transfection, the medium was changed with complete media and further incubated for 6 
hours. The cells were serum starved in the serum-poor (0.25% FBS) medium for 16 
hours prior to the treatment with indicated reagents. After treatment, the cells were 
lysed with reporter lysis buffer. The luciferase and P-galactosidase enzyme activities 
were determined using the Luciferase Assay System and p-galactosidase Enzyme 
System (Promega, Madison, WI) according to the manufacturer’s instruction.
Luciferase activity was normalized to the P-galactosidase activity.
2.2.12. Cell viability assay
HCT-116 cells (0.75 x 104 cells/well) were plated to 96 well plate. The cells 
were serum starved for 24 hours by replacing the culture media with McCoy’s 5A
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media containing 0.25% fetal bovine serum. Then, the media was removed and fresh 
media containing fatty acids were added. The fatty acids were combined with fatty acid 
free albumin at a molar ratio o f  10:1 (fatty acid : albumin) in serum poor medium. After 
culturing for 48 hours, 20 pi o f  3-(4,5-DimethyIthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Sigma) solution (5 pg/ml) were added to each well and incubated for 
another 4 hours. Insoluble formazan precipitates formed in media were solubilized with 
100 fil o f 10% SDS-0.01 N HC1 solution. Absorbance at 595 nm was measured by using 
Bio-Rad plate reader.
2.2.13. Statistical analysis
Data were analyzed by paired t-test. Differences were considered statistically 
significant at P<0.05.
2.3. Results
2.3.1. The effects of n-3 and n-6 PUFAs on COX-2 expression in RAW 264.7 cells
Polyunsaturated fatty acids (PUFAs) such as n-3 and n-6 have diverse effects on 
cells. It is especially known that they can regulate gene expression in macrophages. 
Therefore, this study first examined the effect o f n-3 and n-6 PUFAs on COX-2 gene 
expression in macrophage cell line, RAW 264.7 cells. Serum starved RAW 264.7 cells 
were exposed to indicated concentration o f DHA for 11 hours. Total cell lysates were 
prepared and analyzed by an anti-COX-2 and GAPDH immunoblot analysis. Results 
showed that DHA did not induce COX-2 expression. In this study, "housekeeping 
gene’, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal 
control for COX-2 immunoblot analysis. Figure 2.1 showed that the levels o f  GAPDH 
proteins were constant at all lanes.
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COX-2 Immunoblot
GAPDH Immunoblot
DHA(nM) -  5 10 20 50 100
Figure 2.1. The effects o f  docosahexaenoic acid (DHA) on COX-2 expression in 
RAW 264.7 cells. Cells maintained in serum-poor medium were treated with DHA for 
11 hours. Cell lysates were analyzed by COX-2 or GAPDH immunoblot.
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Next, EPA as another n-3 PUFAs, and AA , LA, and cLA as n-6 PUFAs were 
also tested for their effects on COX-2 expression. All o f the PUFAs that were tested 
did not induce COX-2 expression (Figure 2.2).
2.3.2. Suppression of LPS-induced COX-2 expression by PUFAs
Since lipopolysaccharide can induce COX-2 expression in RAW 264.7 cells, the 
effects of PUFAs on LPS-induced COX-2 expression were tested. Serum starved RAW
264.7 cells were pretreated with each PUFA for 3 hours, and then stimulated with LPS 
(0.1 |ig/ml) in the medium containing each PUFA for 8 hours. All of the PUFAs that 
were tested inhibited LPS-induced COX-2 expression in a dose-dependent manner 
(Figure 2.3, 2.4, 2.5,2.6, and 2.7). There was no difference in the magnitude o f 
inhibition between n-3 and n-6 PUFAs. The levels of GAPDH expression were not 
affected in all PUFAs.
2.3.3. Suppression of other proinflammatory maker gene products, iNOS and IL- 
l a ,  by PUFAs
All PUFAs which were tested also suppressed the induction of inducible nitric 
oxide synthase (iNOS) and interleukin-la (IL -la ) protein in LPS-stimulated RAW 264. 
7 cells (Figure 2.3,2.4, 2.5, 2.6, and 2.7) in a dose-dependent fashion. These results 
indicate that all these PUFAs can suppress the expression o f many other genes whose 
induction is involved in inflammatory reaction in cells.
2.3.4. Inhibition of LPS-induced NF-kB activation by n-3 and n-6 PUFAs
LPS can induce NF-kB activation through IxBa degradation. NF-kB is a 
member o f transcriptional activator protein group and plays an important role in 
controlling inflammatory gene activation. NF-kBs are made up o f dimers that are 
normally confined in the cytoplasm through their association with the IkBs, which mask
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COX-2 Immunoblot
GAPDH Immunoblot
QiM) -  50 100 50 100 50 100 50 100 PC
AA EPA LA cLA
Figure 2.2. The effects of fatty acids on COX-2 expression in RAW 264.7 cells.
Cells maintained in serum-poor medium were treated with indicated concentration of 
each fatty acid for 11 hours. Cell lysates were analyzed by COX-2 or GAPDH 
immunoblot. AA, arachidonic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; 
cLA, conjugated linoleic acid.
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Figure 2.3. Inhibitory effect of docosahexaenoic acid (DHA) on LPS-induced 
expression of COX-2, IL-1, and iNOS in RAW 264.7 cells. Cells maintained in 
serum-poor medium were pretreated with indicated concentration of DHA for 3hours 
and then stimulated with LPS (0.1 pg/ml) in the medium containing DHA for 8hours. 
Cell lysates were analyzed by COX-2, IL -la  or GAPDH immunoblot.
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EPA(|iM) -  -  5 10 20 50
LPS -  + + + + +
Figure 2.4. Inhibitory effect of eicosapentaenoic acid (EPA) on LPS-induced 
expression of COX-2, IL-1, and iNOS in RAW 264.7 cells. Cells maintained in 
serum-poor medium were pretreated with indicated concentration o f EPA for 3hours 
and then stimulated with LPS (0.1 pg/ml) in the medium containing EPA for 8hours. 
Cell lysates were analyzed by COX-2, IL -la  or GAPDH immunoblot.
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LPS -  + + + + + +
Figure 2.5. Inhibitory effect of arachidonic acid (AA) on LPS-induced expression 
of COX-2, IL-1, and iNOS in RAW 264.7 cells. Cells maintained in serum-poor 
medium were pretreated with indicated concentration o f AA for 3hours and then 
stimulated with LPS (0.1 pg/ml) in the medium containing AA for 8hours. Cell lysates 
were analyzed by COX-2, IL -la  or GAPDH immunoblot.
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Figure 2.6. Inhibitory effect of linoleic acid (LA) on LPS-induced expression of 
COX-2, IL-1, and iNOS in RAW 264.7 cells. Cells maintained in serum-poor medium 
were pretrealed with indicated concentration o f  LA for 3hours and then stimulated with 
LPS (0.1 pg/ml) in the medium containing LA for 8 hours. Cell lysates were analyzed 
by COX-2, IL -la  or GAPDH immunoblot.
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cLA(nM) -  -  1 10 50 100 150
LPS -  + + + + + +
Figure 2.7. Inhibitory effect of conjugated linoleic acid (cLA) on LPS-induced 
expression of COX-2, IL-1, and iNOS in RAW 264.7 cells. Cells maintained in 
serum-poor medium were pretreated with indicated concentration o f cLA for 3hours 
and then stimulated with LPS (0.1 pg/ml) in the medium containing cLA for 8 hours. 
Cell lysates were analyzed by COX-2, IL -la  or GAPDH immunoblot.
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their nuclear localization sequence. When cells are activated by pro-inflammatory 
cytokines, oxidants, and LPS, the IicBa are rapidly phosphorylated and degraded to free 
NF-kB which migrates to the nucleus where it binds to cognate DNA binding sites and 
activates gene transcription. Therefore, the degradation of ItcBa parallels the 
appearance of NF-kB in the nucleus and can be assessed by IicBa immunoblotting. 
DHA and LA were tested for their effects on LPS-induced NF-kB activation by IicBa 
immunoblotting. Both DHA and LA inhibited LPS-induced degradation of 
IicBa (Figure 2.8 and 2.9).
2.3.5. The effects of saturated fatty acids on COX-2 expression in RAW 264.7 cells
Since there was no difference between the effects o f n-3 and n- 6  PUFAs on 
LPS-induced COX-2 expression, saturated fatty acids were tested. Cells maintained in 
serum-poor medium were treated with palmitic acid (PA) or stearic acid (SA) for 11 
hours under serum-poor condition. Figure 3.10A showed that palmitic acid (C l6:0) 
induced COX-2 expression in a dose-dependent fashion without any change of GAPDH 
expression. However, stearic acid did not induce COX-2 expression (Figure 2.11 A).
To examine the effect of saturated fatty acids on LPS-induced COX-2 
expression, cells maintained in serum-poor medium were pretreated with palmitic acid 
or stearic acid for 3 hours, and then stimulated with LPS (0.1 ng/ml) in the medium 
containing each fatty acid for 8  hours under serum-poor conditions. PA inhibited LPS- 
induced COX-2 expression in low concentration and increased LPS-induced COX-2 
expression in high concentration (Figure 2.1 OB). However, SA did not show any effect 
on LPS-induced COX-2 expression (Figure 2.1 IB).
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IicBa immunoblot
DHA OM) -  
LPS 4- +  +  +
1 10 50
Figure 2.8. Inhibition o f LPS-induced degradation of IxBa by docosahexaenoic 
acid (DHA) in RAW 264.7 cells. Cells maintained in serum-poor medium were 
pretreated with indicated concentration o f DHA for 3 hours, and then stimulated with 
LPS (0.1 fig/ml) in the medium containing DHA for 30 min. Cell lysates were analyzed 
by IjcBoi immunoblot.
42
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
IicBa immunoblot
LAOiM) -  
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Figure 2.9. Inhibition of LPS-induced degradation of ItcBa by linoleic acid (LA) in 
RAW  264.7 cells. Cells maintained in serum-poor medium were pretreated with 
indicated concentration o f LA for 3 hours, and then stimulated with LPS (0.1 pg/ml) in 
the medium containing LA for 30 min. Cell lysates were analyzed by IicBa 
immunoblot.
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COX-2 Immunoblot
GAPDH Immunoblot
PA(uM) -  5 10 20 50 100 200 PC
COX-2 Immunoblot
GAPDH Immunoblot
PA (|iM) -  -  5 10 20 50 100 200 PC
LPS -  + + + + + + +
Figure 2.10. Inhibitory effects of palmitic acid (PA) on LPS-induced expression of
COX-2 in RAW 264.7 cells. Cells maintained in serum-poor medium were treated 
with PA for 3 hours and then stimulated with LPS (0.1 pg/ml) in the medium containing 
PA for 8  hours. Cell lysates were analyzed by COX-2 or GAPDH immunoblot.
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COX-2 Immunoblot
ifMfcac _m̂g|«w ^PU P »!PP^
GAPDH Immunoblot
SA(^iM) -  5 10 20 50 100 200 PC
B COX-2 Immunoblot
GAPDH Immunoblot
SA(nM) -  -  5 10 20 50 100 200 PC 
LPS -  + + + + + + +
Figure 2.11. The effects of stearic acid (SA) on LPS-induced expression of COX-2 
in RAW 264.7 cells. Cells maintained in serum-poor medium were treated with SA for 
3 hours and then stimulated with LPS (0.1 pg/ml) in the medium containing S A for 8  
hours. Cell lysates were analyzed by COX-2 or GAPDH immunoblot.
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2.3.6. The effects o f DHA on COX-2 expression in HT29 cells
In order to investigate the effects o f PUFAs on COX-2 expression in cancer 
cells, human colon adenocarcinoma cell line, HT29 cells were tested. HT29 cells 
maintained in serum-poor medium were treated with DHA for 11 hours under serum- 
poor conditions. DHA did not induce COX-2 expression (data not shown).
It is known that HT29 cells can induce COX-2 expression by TN Fa, but not by 
LPS. Therefore, to examine the effect of DHA on TNFa-induced COX-2 expression, 
HT29 cells maintained in serum-poor medium were pretreated with DHA for 3 hours, 
and then stimulated with TNFa (20 ng/ml) in the medium containing DHA for 8  hours 
with either serum-poor media and 10% serum media. DHA did not inhibit TNFa- 
induced COX-2 expression under either condition (Figure 2.12).
2.3.7. The effects o f  n-3 and n-6 PUFAs on LPS-induced COX-2 promoter activity 
To determine whether inhibition o f  LPS-induced COX-2 expression by PUFAs
is transcriptionally regulated, the luciferase assay using COX-2 promoter was 
conducted. RAW 264.7 cells, transfected with COX-2 promoter luciferase, were treated 
with DHA for 11 hours. DHA did not affect the promoter activity o f  COX-2 (Figure 
2.13). However, DHA inhibited LPS-induced transcriptional activity o f  COX-2 
promoter in a dose dependent fashion (Figure 2.13). These results correspond with 
those obtained by
Western blot analysis from endogenous COX-2 protein in RAW 264.7 cells (Figure 
2.3). Moreover, LA showed exactly the same effects as DHA (Figure 2.14).
In an attempt to identify the signaling step which is affected by PUFAs, the 
effects o f PUFAs on NF-kB promoter activity induced by constitutively active form of
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Figure 2.12. The effects o f docosahexaenoic acid (DHA) on COX-2 expression in 
TNFa-stimulated HT29 cells. Cells maintained in serum-poor medium were treated 
with DHA for 3 hours and then stimulated with TNFa (20 ng/ml) in the medium 
containing DHA for 8  hours. Cell lysates were analyzed by COX-2 and GAPDH 
immunoblot.








DHA(fiM) — BSA 1 5 10 20 BSA 1 5 10 20
Figure 2.13. Docosahexaenoic acid (DHA) does not activate COX-2 promoter 
activity, but inhibits the induction of COX-2 promoter activity by LPS. RAW
264.7 cells were transfected with lpg  o f COX-2 gene promoter luciferase and 0.5pg of 
p-galactosidase. Transfected cells were treated with DHA and LPS (0. l^g/ml) or DHA 
alone for 11 hours. Luciferase activity was measured and normalized by co-transfected 
p-galactosidase activity. Values represent the mean ± SEM (n=3). *, P<0.05.
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LA(nM) — BSA 1 5 10 20 BSA I 5 10 20
Figure 2.14. Linoleic acid (LA) does not activate COX-2 promoter activity, but 
inhibits the induction of COX-2 promoter activity by LPS. RAW 264.7 cells were 
transfected with lp g  of COX-2 gene promoter luciferase and 0.5pg o f P-galactosidase. 
Transfected cells were treated with LA and LPS (0.1 (ig/ml) or LA alone for 11 hours. 
Luciferase activity was measured and normalized by co-transfected P-galactosidase 
activity. Values represent the mean ± SEM (n=3). *, P<0.05.
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Toll-like receptor 4 (ATlr4) or NF-icB-inducing kinase (NIK) were determined. 
Constitutively active form o f LPS receptor, ATlr4, or NIK can activate transcriptional 
activity o f NF-kB reporter gene. Enhanced NF-kB promoter activity in RAW 264.7 
cells transfected with ATlr4 was inhibited by DHA and LA (Figure 2.15). However, 
enhanced NF-kB promoter activity in RAW 264.7 cells transfected with NIK was not 
inhibited by DHA,LA, PA, or SA (Figure 2.16). These results imply that the potential 
target o f PUFAs is upstream of NIK.
2.3.8. The effects of ligands for peroxisome proliferator-activated receptors 
(PPARs) on COX-2 expression in RAW 264.7 cells
Recent studies demonstrated that PUFAs are ligands for peroxisome proliferator 
activated receptors and can induce COX-2 expression in epithelial cells (Meade et al., 
1999). The present study examined the expression o f PPAR subtypes in RAW 264.7 
cells. Neither o f  PPARa, PPARp, or PPARy was detected by immnoblot analysis in 
RAW 264.7 cells. Wy 14643 and troglitazone, which are known specific ligands for 
PPARa and PPARy, respectively, were used to examine which subtype of PPARs is 
responsible for the COX-2 expression by PUFAs in RAW 264.7 cells. As shown in 
Figure 2.17A and 2.18A, Wy 14643 did not induce COX-2 expression, whereas 
troglitazone showed markedly increased COX-2 expression. In addition, LPS-induced 
COX-2 expression was slightly inhibited by Wy 14643 (Figure 2.17B), whereas TG 
potentiated COX-2 expression induced by LPS (Figure 2.18B). These results indicate 
that the PUFAs show similar effects with PPARa on COX-2 expression and imply that 
the inhibiton o f  PUFAs on LPS-induced COX-2 expression is mediated through the 
activation o f PPARa in RAW 264.7 cells.
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Figure 2.15. Docosahexaenoic acid (DHA) and linoleic acid (LA) inhibit NF-kB 
reporter activity induced by constitutively active form of Toll-like receptor-4 
(ATIr4). RAW 264.7 cells were transfected with 1 pg o f NF-kB-luciferase, 0.5 pg of 
P-galactosidase, and 1 pg o f ATlr4 wt (or mutant form o f ATlr4(P712H) or pcDNA- 
vector). Transfected cells were treated with DHA or LA for 11 hours under serum-poor 
condition. Luciferase activity was measured and normalized by co-transfected P- 
galactosidase activity. ). BSA, bovine serum albumin; DHA, docosahexaenoic acid; 
LA, linoleic acid. Values represent the mean ± SEM (n=3).
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Figure 2.16. Polyunsaturated fatty acids (PUFAs) or saturated fatty acids do not 
inhibit NF-kB reporter activity induced by NF-KB-inducing kinase (NIK). RAW
264.7 cells were transfected with 1 pg o f NF-icB-luciferase, 0.5 pg o f P-galactosidase, 
and 1 pg of NIK wt (or mutant form o f NIK KA or pRK-vector). Transfected cells 
were treated with the indicated fatty acids (FA) for 11 hours under serum-poor 
condition. Luciferase activity was measured and normalized by co-transfected P- 
galactosidase activity. BSA, bovine serum albumin; DHA, docosahexaenoic acid; LA, 
linoleic acid; PA, palmitic acid; SA, stearic acid. Values represent the mean ± SEM 
(n=3).
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Figure 2.17. The effects of WYI4643 (Wy) on COX-2 expression in RAW 264.7 
cells. Cells maintained in serum-poor medium were treated with WY for 3 hours and 
then stimulated with LPS (0 .1  pg/ml) in the medium containing WY for 8  hours. Cell 
lysates were analyzed by COX-2 or GAPDH immunoblot.
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COX-2 Immunoblot
GAPDH Immunoblot
TG(nM) -  5 10 20
COX-2 Immunoblot
GAPDH Immunoblot
TGOiM) -  -  5 10 20 
LPS -  + + + +
Figure 2.18. The effects of troglitazone (TG) on COX-2 expression in RAW 264.7 
cells. Cells maintained in serum-poor medium were treated with TG for 3 hours and 
then stimulated with LPS (0.1 fig/ml) in the medium containing TG for 8  hours. Cell 
lysates were analyzed by COX-2 or GAPDH immunoblot.
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23.9 . The effects o f n-3 fatty acids and n-6 fatty acids on cell proliferation in 
HCT116 cells overexpressing COX-1 or COX-2
Recently, our lab found that the growth o f colon tumor cells xenographed into 
athymic nude mice was suppressed by a fish oil diet (rich n-3 PUFAs) as compared with 
safflower oil diet (rich in n- 6  PUFAs) regardless o f whether COX-1 or COX-2 was 
expressed or not in the cells (unpublished data). Therefore, MTT assay was conducted 
to investigate the effects o f dietary fatty acids on cell growth using human colorectal 
adenocarcinoma cells (HCT-116) stably transfected with COX-1 or COX-2 cDNA [see 
APPENDIX 1]. The results were compared with an in vivo study. HCT-116 cells 
transfected with the control vector, COX-1, or COX-2 were grown for 48 hours in the 
media containing EPA, DHA, or LA. If cells are maintained in the media containing 10 
% FBS, growth factors incorporated from serum may contribute to the cell growth. 
Therefore, in order to eliminate any masking effect, the media containing 0.25 % FBS 
was used for MTT assay. Both EPA and DHA inhibited cell growth in all three cells 
groups, whereas LA did not inhibit the cell growth (Figure 2.19). It appears that the 
growth inhibitory effect o f DHA was greater than EPA. No significant difference 
between BSA control and LA was seen in all three cells groups.
2.3.10. Expression of enzymatically active COX proteins in IEC-6 cells transfected 
with COX cDNA
This experiment was originally conducted to study whether or not suppression 
of tumor cell growth by dietary fatty acids is mediated through inhibition of COX. 
HCT-116 cell line was selected as colon cancer cell to be transfect with COX-1 or 
COX-2 cDNA. IEC - 6  cell line was selected as a control normal cell to be transfect with 
COX-1 or COX-2 cDNA. IEC- 6  cells were infected with retroviral particles which
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Figure 2.19. Suppression o f cell proliferation by n-3 fatty acid in HCT116 cells 
which are expressing (A) control vector, (B) COX-1, or (C) COX-2. LA, linoleic 
acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid. Values are mean o f six 
replicates.
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were produced by phoenix cells transfected with COX-1 or COX-2 cDNAs. To 
distinguish with endogeneous COX-1 or COX-2 protein. COX-1 and COX-2 cDNA 
was tagged with epitope ‘flag’, which is 8  amino acids (N-Asp-Tyr-Lys-Asp-Asp-Asp- 
Asp-Lys-C) at the C-terminus o f COX cDNA cloned in pLinx vector. Therefore, COX 
is expressed in the form o f the fusion protein ‘COX-Flag’. To select the stable clones 
expressing enzymatically active COX-1 (Figure 2.20) or COX-2 (Figure 2.21) protein, 
each clone was screened under neomycin (800 pg/ml). The expression level o f COX-1 
or COX-2 protein in these stable clonal cells was first examined by COX-1 or COX-2 
immunoprecipitation with polyclonal anti-Flag antibodies followed by immunoblotting 
with COX-1 or COX-2 antibodies. Figure 2.20 and 2.21 show that COX-1 or COX-2 
transfected cells with no tetracylcine (lane 3) expressed high levels o f  COX-1 and 
COX-2 protein. Their expression was almost completely suppressed by incubating the 
cells with tetracycline (lane 4). No DNA (lane 1) or control vector (lane 2) expressing 
cells did not express COX protein.
In addition, the enzymatic activity o f  COX-1 or COX-2 protein was also 
determined by radioimmunoassay for PGE2 . Figure 2.20B and 2 .2IB  show that COX- 
1 or COX-2 overexpressing cells produce high levels o f PGE2 in a tetracycline- 
regulated manner. These data indicate that COX-1 or COX-2 proteins expressed in 
these cells are enzymatically active.
In order to investigate the possible relationship between COX overexpression 
and tumorigenesis, IEC- 6  cells overexpressing COX-1 or COX-2 (2 x 106 cells) were 
injected into female athymic nude mice (NCr-nu/nu) subcutaneously. However, they 
did not form tumors in athymic nude mice.
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Figure 2.20. Tetracycline-regulated expression of the COX-1 protein and PGE2 
production in normal rat intestinal epithelial cells (IEC-6). (A) Whole cell lysates 
from stable clonal cells were immunoprecipitated with polyclonal anti-Flag antibodies 
and immunoblotted with COX-1 antibodies. (B) COX-1 enzyme activity was 
determined by radioimmunoassay for PGE2 in the same stable clonal cells used at (A).
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Figure 2.21. Tetracycline-regulated expression of the COX-2 protein and PGE2 
production in normal rat intestinal epithelial cells (IEC-6). (A) Whole cell lysates 
from stable clonal cells were immunoprecipitated with polyclonal anti-Flag antibodies 
and immunoblotted with COX-2 antibodies. (B) COX-2 enzyme activity was 
determined by radioimmunoassay for PGE2 in the same stable clonal cells used at (A).
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2.4. Discussion
Dietary manipulation o f fatty acids can reduce the severity o f a number o f 
inflammatory and immune disorders and inhibit growth of certain tumors (Kromhout et 
al., 1985; Meydani et al., 1993; Goodnight, 1996). Several studies suggested that the 
anti-inflammatory effects o f dietary fatty acids might occur by modulating the 
macrophage intracellular signal pathways which, in turn, influence gene activation and 
cytokines production (Meydani and Dinarello, 1993; Lo et al., 1999). Macrophages 
can be stimulated to produce many kinds o f cytokines such as TNFa and interferon-y. 
The inhibitory effect o f polyunsaturated fatty acids (PUFAs) on cytokine production has 
been shown in many human studies. Endres et al. (1989) reported that n-3 PUFAs 
suppress production o f cytokines such as TN Fa and IL-1 from stimulated mononuclear 
cells. Meydani et al. (1993) also showed that production of cytokines IL-1, TNFa, and 
IL- 6  by mononuclear cells was significantly reduced in subjects after consumption o f 
the low-fat, high-fish diet. However, the data from in vitro and in vivo studies are 
conflicting in terms of the effects o f fish oil on macrophage cytokine production in 
response to LPS. Sato et al. (1992) reported that human peripheral monocytes 
incubated in EPA-rich media for 6  hours produced more TNF in response to LPS 
stimulation. The difference between these studies might be related to differences in the 
feeding duration, species variations, and the percentage of EPA and DHA in the diets.
It has been observed that dietary n-3 fatty acids can relieve the symptoms of 
rheumatoid arthritis and this is associated with decreased PGE2 synthesis. The 
molecular mechanisms on the anti-inflammatory regulation by dietary fatty acids are 
not well understood. Results from the present study suggest that the antiinflammatory
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and immunomodulating effects o f n-3 PUFAs are mediated through COX-2 
independent pathways in macrophages. The important finding o f the present study is 
that both n-3 and n- 6  PUFAs inhibit LPS-induced COX-2 expression in macrophages. 
Results from Western blot analyses demonstrate that both n-3 and n- 6  PUFAs inhibit 
LPS-induced COX-2 expression in RAW 264.7 cells, whereas they do not induce COX- 
2 expression in the absence of LPS. On the other hand, saturated fatty acids showed 
somewhat different effects on COX-2 expression. Palmitic acid (C l6:0) induced COX-2 
expression, and inhibited LPS-induced COX-2 expression at low concentrations, but it 
enhanced LPS-induced COX-2 expression at higher concentrations. However, stearic 
acid (C 18:0) by itself did not induce COX expression and did not show any effect on 
LPS-induced COX-2 expression. Therefore, there were different effects on COX-2 
expression only between PUFAs and saturated fatty acids, not between n-3 and n- 6  
PUFAs. There are some conflicting reports on the effects o f PUFAs on COX-2 
expression. Badawi et al. (1998) reported on the effect o f dietary n-3 and n- 6  PUFAs 
on the expression o f COX-1 and COX-2 in rat mammary glands. They demonstrated 
that n- 6  PUFAs upregulated COX-2 and, to some extent, COX-1 expression, but n-3 
PUFAs did not affect COX expression. Singh et al. (1997) reported that com oil (rich 
in n- 6  PUFAs) promote colon tumorigenesis by upregulating the COX-2 expression and 
fish oil (rich in n-3 PUFAs) may exert its antitumor effect by inhibiting the COX-2 
expression. So, they suggested differential effects o f PUFAs on COX-2 expression. 
Recently Meade et al. (1999) however, demonstrated that both n-3 and n- 6  fatty acids 
by themselves induce COX-2 expression in mammary epithelial cells. However, results 
from this study indicate that DHA does not induce COX-2 expression and does not
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inhibit TNFa-induced COX-2 expression in human colon adenocarcinoma cell line, 
HT29 cells. These difference might be related to difference in the cell types.
Inducible nitric oxide synthase (iNOS) is the enzyme responsible for the 
production of nitric oxide (NO). It is widely accepted that excessive NO production in 
inflammation is associated with cellular injury and other pathological developments. 
Interleukin-la (IL -la) is one of the key mediators in the response to microbial 
invasion, immunologic reactions, inflammatory response, and tissue injury. 
Overproduction of IL-1 contributes to the pathogenesis o f several chronic and acute 
inflammatory diseases including rheumatoid arthritis, cancer cachexia, atherosclerosis, 
and gram-negative bacteria induced infection. In this study, PUFAs were shown to 
inhibit not only COX-2 expression but also the expression o f  iNOS and IL -la  induced 
by LPS. These results suggest that PUFAs also inhibit the expression o f other pro- 
inflammatory marker gene products in response to inflammatory stimuli. Consistant 
with the present study, the inhibition o f transcription o f the murine iNOS gene by DHA 
in Raw 264.7 cells has been reported by Khair-El-Din et al. (1996). But, they did not 
examine the n- 6  PUFAs. Ohata et al. (1997) reported that the n-3 PUFAs (DHA, EPA, 
and a-linolenic acid) suppressed NO production in macrophages activated with LPS by 
inhibiting the induction of iNOS gene expression. On the other hand, n- 6  PUFAs, n-9 
PUFAs and a saturated fatty acid did not inhibit NO production.
Results from promoter-reporter assays demonstrated that both n-3 and n- 6  
PUFAs inhibit LPS-induced COX-2 expression at the transcriptional level and support 
the results obtained by Western blot analysis from endogenous COX-2 protein in RAW
264.7 cells.
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Lo et al. (1998) suggested that COX-2 gene expression by LPS-stimulated 
macrophages is dependent on N F -kB . Lo et al. (1999) also reported that the inhibitory 
effect o f eicosapentaenoic acid (EPA) on TNF gene transcription and protein 
elaboration in LPS-stimulated macrophages is mediated by altering the N F -kB  activity. 
However, they did not examine the effects o f n- 6  PUFAs. Therefore, this study 
investigated the effects of n-3 and n- 6  PUFAs on N F-kB  signal transduction pathways. 
NF-kB is a member o f transcriptional activator proteins and plays an important role in 
controlling inflammatory gene activation. N F -kB s are composed of dimers that are 
normally confined in the cytoplasm through their association with the IkB s, which mask 
their nuclear localization sequence. When cells are activated by pro-inflammatory 
cytokines, oxidants, and LPS, the IkB o . are rapidly phosphorylated and degraded to free 
NF-kB which migrates to the nucleus where it binds to cognate DNA binding sites and 
activates gene transcription. Therefore, the degradation o f IkB  parallels the appearance 
of NF-kB in the nucleus. As shown in Figure 2.8 and 2.9, both DHA and LA inhibited 
LPS-induced N F -kB  activation, suggesting an inhibitory action on N F -kB  dependent 
other genes. Again, n-3 PUFAs and n- 6  PUFAs showed the same inhibitory effect on 
NF-kB activation in macrophages.
In an attempt to identify the signaling step which is affected by PUFAs, the 
effects of PUFAs on NF-kB promoter activity induced by constitutively active form of 
toll-like receptor 4 (ATlr4) or NF-KB-inducing kinase (NIK.) were determined. ATlr4 is 
the constitutively active form of the LPS receptor and activates NF-kB. NIK is a 
member of the MAP kinase kinase kinase (MAPKKK) family and activates NF-kB
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through phosphorylation and activation o f  the IKKs, which are IicB kinases (Ghosh, 
1997). Enhanced NF-kB promoter activity in RAW 264.7 cells transfected with ATlr4 
was inhibited by DHA or LA (Figure 2.15). However, enhanced NF-kB promoter 
activity in RAW 264.7 cells transfected with NIK was not inhibited by DHA or LA 
(Figure 2.16). These results suggest that the potential target o f PUFAs is upstream o f 
NIK. The molecular target o f PUFAs that mediate the inhibition o f the LPS-induced 
NF-kB activation still needs to be identified.
Recently, it was demonstrated that peroxisome proliferator-activated receptors 
(PPARs) are key regulators o f lipid homeostasis and play a role in inflammation and 
cell proliferation. Recent study showed that fatty acids are ligands for PPARs 
(Desvergne and Wahli, 1999) and can induce COX-2 expression in epithelial cells, 
suggesting that they are potential modulators for gene expression (Meade et al., 1999). 
Staels et al. (1998) reported that PPARa activator can inhibit the expression o f various 
genes involved in the inflammatory response, including COX-2, in smooth muscle cells. 
They concluded that this inhibition o f COX-2 induction occurs transcriptionally as a 
result of repression o f  NF-kB signaling by PPARa. On the other hand, Rossi et al. 
(2000) recently reported that PPARy activator, 15-deoxy-A12' ,4-prostaglandin T  (15d- 
PGJ2) inhibits NF-kB through PPARy-independent mechanism. They demonstrated that 
15d-PGJ2 inhibits NF-kB by a direct covalent modification and inhibition o f IkB kinase 
P (IKK P), which is a  responsible enzyme for the activation of NF-kB. Ricote et al.
(1998) suggested that PPARy is involved in the regulation o f inflammatory responses. 
They demonstrated that PPARy is markedly upregulated in activated macrophages, and 
PPARy ligands inhibit expression of iNOS, gelatinase B and scavenger receptor A
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genes. Although Ricote et al. (1998) reported that RAW 264. 7 cells express very low 
levels of PPARy mRNA, immunoblot analysis from the present study did not detect 
any PPAR subtypes in RAW 264.7 cells [see APPENDIX 3]. The present study also 
tested the effects o f a known PPARa activator, Wy 14643, and a known PPARy 
activator, troglitazone, on COX-2 expression. Wy 14643 was shown to inhibit LPS- 
induced COX-2 expression, whereas Wy 14643 alone did not induce the COX-2 
expression. On the other hand, troglitazone alone induced COX-2 expression, and 
troglitazone potentiated LPS-induced COX-2 expression. Therefore, PUFAs and 
PPARa activators show similar effects on COX-2 expression in macrophages. It needs 
to be determined whether the inhibitory effects o f PUFAs on LPS-induced COX-2 
expression are indeed mediated through the activation o f  PPARa in RAW 264.7 cells.
Recently it was found that the growth of colon tumor cells xenographed into 
athymic nude mice was suppressed by the fish oil diet (rich n-3 PUFAs) as compared 
with safflower oil diet (rich in n- 6  PUFAs) regardless o f whether COX-1 or COX-2 is 
expressed or not in the cells (unpublished data). As an in vitro test, MTT assay was 
conducted to investigate the effects o f dietary fatty acids on cell proliferation using 
human colorectal adenocarcinoma cells (HCT116) stably transfected with COX-1 or 
COX-2. As shown in Figure 2.19, both EPA and DHA inhibited proliferation of all 
cell-lines (control vector, COX-1, and COX-2 transfected cells). However, LA did not 
inhibit cell proliferation. The growth inhibitory effect o f  DHA was greater than that o f 
EPA. The effects o f fatty acids were not different among three cell groups. Therefore, 
these results corroborate data obtained by in vivo experiments. If the efficacy of n-3 
PUFAs to suppress tumor cell growth both in vitro and in vivo is primarily mediated
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through inhibition o f COX, the growth o f COX overexpressing cell should differ from 
the growth o f control vector-transfected cells. Therefore, these results indicate that the 
suppression o f tumor growth by n-3 PUFAs is mediated through COX-independent 
pathways. The signaling pathways through which n-3 PUFAs suppress tumor growth 
still remain to be identified.
Taken together, DHA and EPA were much more potent than LA in inhibiting 
the cell proliferation, whereas there was no difference between n-3 and n- 6  PUFAs in 
inhibiting LPS-induced COX-2 expression. Thus, these results suggest that the 
signaling pathways through which PUFAs inhibit tumor cell growth and LPS-induced 
COX-2 expression may be different.
Further studies are needed to resolve how n-3 PUFAs unlike n- 6  PUFAs exert 
their anti-inflammatory effects and inhibitory effects on tumor cell growth.
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CHAPTER3
THE EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON 
CYCLOOXYGENASE-2 EXPRESSION
3.1. Introduction
Colon cancer is one o f the leading causes o f cancer deaths in western countries, 
with an estimated 94,100 new cases and 46,600 deaths in the United States in 1997 
(Parker et al., 1997). Recent epidemiological studies indicate an inverse relationship 
between the intake o f non-steroidal anti-inflammatory drugs (NSAIDs), especially 
aspirin, and colon cancer risk (Thun et al., 1993; Giovannucci et al., 1994). Animal 
studies have also demonstrated colon tumor inhibition by several NSAIDs, including 
aspirin, sulindac, ibuprofen, and piroxicam (Reddy et al., 1993; Rao et al., 1995). 
Results from clinical studies in patients with familial adenomatous polyposis indicate 
that administration o f sulindac causes a reduction o f polyps, which are precursors o f 
colon cancer (Gardiello et al., 1993).
The major pharmacological action o f NSAIDs is the inhibition of 
cyclooxygenase (COX). COX, also known as prostaglandin endoperoxide H synthase, 
is the rate-limiting enzyme for prostaglandins (PGs) production. There are at least two 
iso forms of COXs, which are known as COX-1 and COX-2. COX-1 is constitutively 
expressed in most type o f  cells, whereas COX-2 is mitogen-inducible.
The mechanisms by which NSAIDs inhibit colon carcinogenesis are not yet 
clearly understood. Possible mechanisms include induction of apoptosis in cancer cells 
(Piazza et al., 1997), and inhibition of COX-2, which, in turn, suppresses PG production 
(Rigas et al., 1993; Mamett, 1992). It has been reported that COX-2 expression is 
elevated in colorectal tumors (Sano et al., 1995). Oshima et al. (1996) reported that
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polyp formation in APC 716 knockout mice which were crossed with COX-2 knockout 
mice were significantly reduced. Xu et al., (1999) also reported that aspirin and sodium 
salicylate suppress COX-2 gene transcription induced by IL-1 in human endothelial 
cells. These results suggest that the beneficial effect of NSAIDs in reducing the risk o f 
colon cancer is mediated through the COX-dependent mechanism.
However, recently, some NSAIDs have been demonstrated to act as peroxisome 
proliferators, suggesting that they may also regulate gene expression as part o f their 
chemopreventative mechanism (Lehmann et al., 1997). In addition, Meade et al. (1999) 
demonstrated that some NSAIDs and PGs activate peroxisome proliferator-activated 
receptors (PPARs) and enhance COX-2 expression, suggesting that chemopreventive 
action of NSAIDs are mediated through COX-2-independent mechanism.
In order to clarify these two conflicting theories, our laboratory examined signal 
pathways through which NSAIDs modulate COX-2 expression in HT-29 colon cancer 
cell line (unpublished data). Results indicate that the NSAIDs have two opposing 
effects on COX-2 expression. That is, the NSAIDs inhibit TNFa-induced COX-2 
expression, while NSAIDs alone can induce COX-2 expression. Furthermore, their 
inhibitory action on TNFa-induced COX-2 expression results partly from the 
suppression of NF-kB. Thus, in order to verify that two opposing effects of NSAIDs 
are restricted to only cancer cells, the present study examined their effects on COX-2 
expression in normal intestinal cell line, IEC- 6  cells. Results from the present study 
will help to understand the mechanisms of the action of NSAIDs in inflammatory 
disease and tumorigenesis.
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3.2. Materials and methods
3.2.1. Materials
Flufenamic acid, indomethacin, and Tumor necrosis factor a  were purchased 
from Sigma Chemical Company (St. Louis, MO). Sulindac sulfide was provided by Dr. 
G.A. Piaza (Cell pathways, Inc., Aurora, CO). PD98059 and SB203580 were 
purchased from Calbiochem (La Jolla, CA). Antibodies for ItcBa were purchased from 
Santa Cruz Biotech (Santa Cruz, CA). Donkey anti-rabbit immunoglobulin G (IgG) 
antibodies conjugated to horseradish peroxidase was purchased from Amersham 
Pharmacia Biotech (Arlington Heights, IL). Enhanced chemiluminescence (ECL) 
western blotting detection reagents were purchased from Amersham Corp (Piscataway, 
NJ). All other reagents were purchased from Sigma unless described.
3.2.2. Cell culture
IEC- 6  cells (rat normal small intestine cell line, ATCC CRL-1592) was cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM, GIBCO-BRL) containing 5% (v/v) 
heat-inactivated fetal bovine serum (FBS, Intergen), 0.1 U/ml of insulin, and 100 
units/ml penicillin and 100 pg/ml streptomycin (GIBCO-BRL) in a 5% C0 2 /9 5 % air 
humidified atmosphere at 37°C. Media were changed every other day.
3.2.3. Preparation o f whole cell lysates
After treatment, cell media were removed and cells were rinsed twice with cold 
PBS. Then 0.5 ml of ice cold RIPA buffer [see APPENDIX 4] were added to 60 mm 
cell culture dishes. After 20 min incubation on ice, cells were collected by scraping the 
dishes with a cell scraper and transferred to 1.5 ml microcentrifuge tubes. After 
sonification (7 strokes x 5), cell lysates were centrifuged at 10,000xg for 10 min at
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4°C. The supernatant fluid is whole cell lysates. The protein concentration was 
measured using Bio-Rad protein assay reagents (Bio-Rad Laboratories, Richmond, CA).
3.2.4. SDS-PAGE and western blotting
Whole cell lysates were boiled for 5 min and electrophoretically resolved on a 
8 % polyacrylamide vertical slab gel [see APPENDIX 4] with an overlay o f 4% 
polyacrylamide gel along with prestained SDS-PAGE molecular weight markers 
(Biorad). Electrophoretically resolved proteins were electrotransfered onto PVDF 
membrane in a electrophoretic transfer cell (Biorad) containing transfer buffer [see 
APPENDIX 4], After transblotting the electrophoretically resolved proteins, the blots 
were blocked with 5% (w/v) nonfat dry milk (NFDM, Carnation) dissolved in 
phosphate buffered saline-0.1 % (v/v) Tween 20 (PBS-T) overnight at 4°C to prevent 
non-specific binding o f antibodies. The blots were then incubated with polyclonal anti- 
COX-2 antibody diluted 1:5000 in PBS-T containing 5% (w/v) NFDM for 1 hour.
Blots were washed in PBS-T and reincubated with anti-rabbit IgG coupled to 
horseradish peroxidase diluted 1:5000 in PBS-T containing 5% (w/v) NFDM. The blots 
were thoroughly washed in excess PBS-T and probed with the enhanced 
chemiluminescence (ECL) western blot detection system (Amersham Corp.). The blots 
were exposed on an X-ray film (Kodak) and the films were developed.
For GAPDH immunoblotting, membranes used for COX-2 immunoblots were 
stripped in the stripping buffer [see APPENDIX 4] at 54 °C for 1 hour, reprobed with 
1:10,000 dilution of GAPDH antibody, and followed by incubation with anti-rabbit IgG 
coupled to horseradish peroxidase diluted 1:5000 in PBS-T containing 5% (w/v)
NFDM. The blots were thoroughly washed in excess PBS-T and probed with the
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enhanced chemiluminescence (ECL) western blot detection system (Amersham Corp.)- 
The blots were exposed on an X-ray film (Kodak) and the films were developed.
3 3 . Results 
33 .1 . COX-2 expression induced by TNFa is potentiated by flufenamic acid, 
sulindac sulfide or indomethacin in IEC-6 cells
Recently, it was found that some non-steroidal anti-inflammatory drugs
(NSAIDs), such as flufenamic acid and sulindac sulfide, induce COX-2 expression and
also inhibit activation o f NF-kB and COX-2 expression induced by TNFa in a human
colon adenocarcinoma cell line, HT29 cells, suggesting that NSAIDs have two
opposing effects on COX-2 expression (Paik et al., unpublished data).
The present study was conducted to determine the effect o f NSAIDs on COX-2
expression in normal cells. A rat normal small intestine cell line, IEC-6 , was chosen.
The effect of flufenamic acid on COX-2 expression in IEC- 6  cells is shown in Figure
3.1. In the absence o f other COX-2 inducers, flufenamic acid induced COX-2 
expression in a dose-dependent fashion (Figure 3.1.A). TNFa induced COX-2 
expression in IEC- 6  cells. Pretreatment o f the cells with flufenamic acid leads to the 
potentiation of TNFa-induced expression o f COX-2 protein (Figure 3.1.B). These 
results suggest differential effects on mitogen-stimulated COX-2 expression in normal 
cells and cancer cells.
Sulindac sulfide and indomethacin show similar effects on COX-2 expression in 
IEC- 6  cells. They also induce COX-2 expression in a dose-dependent fashion (Figure
3.2.A and 3.3.A). TNFa-induced COX-2 expression is potentiated by sulindac sulfide 
or indomethacin in IEC- 6  cells (Figure 3.2.B and 3.3.B).
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Figure 3.1. COX-2 expression induced by TNFa is potentiated by flufenamic acid 
(Flu) in IEC-6 cells. Cells maintained in serum-poor medium were treated with Flu 
alone for 11 hours (A), or pretreated with Flu for 3 hours and then stimulated with 
TN Fa (20 ng/ml) in the medium containing Flu for 8  hours (B). Cell lysates were 
analyzed by COX-2 or GAPDH immunoblot.
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Figure 3.2. COX-2 expression induced by TNFa is potentiated by sulindac sulfide 
(Si) in IEC-6 cells. Cells maintained in serum-poor medium were treated with Si alone 
for 11 hours (A), or pretreated with Si for 3 hours and then stimulated with TNFa (20 
ng/ml) in the medium containing Si for 8 hours (B). Cell lysates were analyzed by 
COX-2 or GAPDH immunoblot.
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Figure 3.3. COX-2 expression induced by TNFa is potentiated by indomethacin 
(Indo) in IEC-6 cells. Cells maintained in serum-poor medium were treated with Indo 
alone for 11 hours (A), or pretreated with Indo for 3 hours and then stimulated with 
TNFa (20 ng/ml) in the medium containing Indo for 8  hours (B). Cell lysates were 
analyzed by COX-2 or GAPDH immunoblot.
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3.3.2. Inhibition of MAP kinases by inhibitors of MAP kinases, PD98059 and 
SB203580, leads to the suppression of COX-2 expression induced by flufenamic 
acid in IEC-6 cells
PD98059 (2’-amino-3’-methoxyflavone) is a known specific inhibitor o f MAP 
kinase kinase (MEK), which phosphorylates and activates MAP kinase. SB203580 [4- 
(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl) 1 H-imidazole] is known to 
be a specific inhibitor o f p38 MAP kinase. Using these specific MAP kinases 
inhibitors, the present study examined whether inhibiting MAP kinases affects the 
expression of COX-2 induced by flufenamic acid in IEC- 6  cells.
IEC- 6  cells were maintained in serum-poor medium and pretreated with one o f 
two different concentrations o f PD98059 (10 and 50 pM) or SB203580 (15 and 30 pM) 
for 3 hours; these concentrations were used based on a review o f literatures that show 
their effects on MAP kinases. Cells were then further treated with a combination o f 
flufenamic acid (400 pM) and PD98059 or SB203580 for 8  hours. Flufenamic acid- 
induced expression o f COX-2 was partially inhibited by PD98059 at the concentration 
o f 10 pM and completely inhibited at the concentration o f 50 pM (Figure 3.4.A). 
Similarly, flufenamic acid-induced COX-2 expression was completely inhibited by 
SB203580 at the concentration o f 30 pM (Figure 3.4.B). The levels of GAPDH 
proteins used as an internal control were constant at all lanes.
3.3.3. Flufenamic acid and sulindac sulfide inhibit TNFa-induced NF-kB 
activation in IEC-6 cells
In order to verify whether the induction o f  COX-2 by NSAIDs is mediated by 
NF-kB activation, the effects o f flufenamic acid and sulindac sulfide on the activation 
o f NF-kB were examined in unstimulated and TNFa-stimulated IEC- 6  cells. The results 
from IxB a immunoblot showed that flufenamic acid and sulindac sulfide alone do not
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Figure 3.4. COX-2 expression induced by flufenamic acid (Flu) is inhibited by 
MEK inhibitor (PD98059) or p38 inhibitor (SB203580) in IEC-6 cells. (A) Cells 
maintained in serum-poor medium were pretreated with PD98059 for 3 hours and then 
further treated with a combination of Flu (400 pM) and PD98059 for 8  hours. (B) Cells 
maintained in serum-poor medium were pretreated with SB203580 for 3 hours and then 
further treated with a combination of Flu (400 pM) and SB203580 for 8  hours. Cell 
lysates were analyzed by COX-2 or GAPDH immunoblot.
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induce the degradation o f ItcBot indicating that flufenamic acid- or sulindac sulfide- 
induced expression o f COX-2 is not mediated through the activation of NF-kB (Figure 
3.5.A and B). TNFa-stimulated activation o f NF-kB was suppressed by flufenamic 
acid or sulindac sulfide in a dose-dependent fashion (Figure 3.6.A and B). However, 
indomethacin did not inhibit TNFa-stimulated activation of NF-kB (Figure 3.6.C). 
These results indicate that inhibition of TNFa-stimulated activation o f NF-kB by 
flufenamic acid or sulindac sulfide is not sufficient to inhibit TNFa-induced COX-2 
expression in IEC- 6  cells.
3.4. Discussion
The major pharmacological action o f non-steroidal anti-inflammatory drugs 
(NSAIDs) is the inhibition of cyclooxygenase (COX). However, some studies recently 
reported that NSAIDs exert their anti-inflammatory effect through a COX-2 
independent pathway. Meade et al., (1999) demonstrated that fatty acids, 
prostaglandins, and NSAIDs, compounds that are substrates, products, and inhibitors, 
respectively, o f COX enzymatic activity, induce COX-2 expression in both mammary 
cells and colonic epithelial cells. They found that NSAIDs, which can activate PPARa, 
but not PPARy, induce transcription o f COX-2. Jiang et al. (1998) also showed that 
PPARy agonists inhibit the production o f inflammation cytokines in human monocyte 
suggesting PPARy-dependent mechanisms in anti-inflammatory response.
Results from a previous study in our laboratory demonstrated that NSAIDs have 
two opposing effects on COX-2 expression in human colon cancer cell line, HT-29.
One is the inhibitory effect on mitogen-induced COX-2 expression. The other is the 
inducing effect on COX-2 expression in the absence o f  stimulators. However, results
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Figure 3.5. NSAIDs alone do not induce degradation of IicBa in IEC - 6  cells. (A)
Cells maintained in serum-poor medium were treated with flufenamic acid (Flu) for 
indicated time periods. (B) Cells maintained in serum-poor medium were treated with 
sulindac sulfide (Si) for indicated time periods. Cell lysates were analyzed by IicBa 
immunoblot.
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Figure 3.6. Flufenamic acid (Flu) and sulindac sulfide (Si), but not indomethacin 
(Indo), inhibit TNFa-induced degradation of IicBa in IEC-6 cells. (A) Cells 
maintained in serum-poor medium were pretreated with flufenamic acid (Flu) for 3 
hours and then stimulated with TN Fa (20 ng/ml) in the presence o f Flu for 8  hours. (B) 
Cells maintained in serum-poor medium were pretreated with sulindac sulfide (Si) for 3 
hours and then stimulated with T N Fa (20 ng/ml) in the presence o f Si for 8  hours. (C) 
Cells maintained in serum-poor medium were pretreated with indomethacin (Indo) for 3 
hours and then stimulated with TN Fa (20 ng/ml) in the presence o f Indo for 8  hours. 
Cell lysates were analyzed by IicBa immunoblot.
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from the present study indicate that NSAIDs do not show these opposing effects on 
COX-2 expression in normal intestinal cell line, IEC-6. Results from Western blot 
analyses showed that NSAIDs alone induce COX-2 expression and they potentiate 
TNFa-induced COX-2 expression. All NSAIDs (flufenamic acid, sulindac sulfide, and 
indomethacin) which were tested here showed similar effects.
The inhibitors of extracellular-signal-regulated protein kinase (ERK), and p38 
MAP kinase inhibit the flufenamic acid-induced COX-2 expression. On the other hand, 
the previous study in HT-29 cells showed that flufenamic acid- or sulindac sulfide- 
induced COX-2 expression was not affected by either the inhibitors o f  p38 or MEK, 
implying that flufenamic acid- or sulindac sulfide- induced COX-2 expression is not 
mediated through the activation o f p38 or MEK in HT-29 cells. These results indicate 
that unlike the previous study in HT-29 cells, flufenamic acid-induced COX-2 
expression is at least partly mediated through activation o f MAPKs in IEC-6 cells.
The results from IicBa immunoblot showed that NSAIDs alone do not induce 
the degradation of IicBa in IEC-6 cells, indicating that flufenamic acid- or sulindac 
sulfide-induced COX-2 is not mediated through the activation of NF-kB. In the 
previous study, similar results were obtained in HT-29; flufenamic acid, sulindac 
sulfide and indomethacin did not induce degradation o f hcBa. TNFa-stimulated 
activation of NF-kB was suppressed by flufenamic acid or sulindac sulfide. But, 
indomethacin did not inhibit TNFa-stimulated activation of NF-kB. It was already 
known that indomethacin is a PPARy activator and does not inhibit NF-kB activation 
(Yin et al., 1998).
80
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Similarly, TNFa-induced NF-kB activation in HT-29 cells was inhibited by 
flufenamic acid and sulindac sulfide, but not by indomethacin, all o f which are 
PPARy ligands. These results suggest that inhibition by flufenamic acid or sulindac 
sulfide on TNFa-induced NF-kB activation is not mediated through the activation o f 
PPARs.
Furthermore, it was likely that NSAIDs, which do not inhibit TNFa-induced 
NF-kB activation, can not inhibit TNFa-induced COX-2 expression in HT-29 cells. 
However, results from the present study indicate that inhibition o f  TNFa-stimulated 
activation o f  NF-kB by flufenamic acid or sulindac sulfide is not sufficient to inhibit 
TNFa-induced COX-2 expression in IEC-6 cells.
The molecular target through which flufenamic acid inhibits TNF-a induced 
NF-kB activation still needs to be identified. Since the NF-kB pathway is involved in 
both the pathogenesis o f the inflammatory response and in cellular growth control, this 
pathway is also a potential target for inhibition by some NSAIDs. Yamatomo et al.
(1999) recently demonstrated that sulindac and its metabolites, sulindac sulfide and 
sulindac sulfone, inhibit IkB kinase P (IKKP), the protein kinase phosphorylating 
IkBo . Inhibition o f IKXp prevents IkBo degradation and thus prevents NF-kB- 
mediated gene expression.
Taken together, results from the present study indicate that some NSAIDs show 
differential effects on mitogen-stimulated COX-2 expression in normal cells and cancer 
cells.
81
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 4 
SUMMARY AND CONCLUSIONS
The purpose o f this study was to investigate the mechanism o f PUFAs and 
NSAIDs on the regulation o f COX-2 expression. The results demonstrate that 
signaling pathways through which PUFAs inhibit tumor cell growth and LPS-induced 
COX-2 expression may be different. Both n-3 and n-6 PUFAs inhibit LPS-induced 
COX-2 expression in macrophages, whereas they do not induce COX-2 expression in 
the absence of LPS. Both n-3 and n-6 PUFAs also inhibit LPS-induced COX-2 
expression at the transcriptional level. They also showed an inhibitory effect on LPS- 
induced NF-kB activation, suggesting an inhibitory action on other NF-kB dependent 
genes. Results from the reporter gene assay indicate that the potential target o f PUFAs 
appears to be upstream o f NIK. The molecular target of PUFAs that mediate the 
inhibition o f the LPS-induced NF-kB activation still needs to be identified. PUFAs 
were shown to inhibit not only COX-2 expression but also the expression o f  iNOS and 
IL -la  induced by LPS. These results suggest that PUFAs also inhibit the expression of 
other pro-inflammatory marker gene products in response to inflammatory stimuli. In 
addition, results from in vitro cell proliferation study indicate that the growth o f colon 
tumor cells is suppressed by n-3 PUFAs as compared with n-6 PUFAs regardless o f 
whether COX-1 or COX-2 is expressed or not in the cells.
Unlike the results from the previous study in human colon carcinoma cells, 
NSAIDs, especially flufenamic acid and sulindac sulfide, upregulate the expression of 
COX-2 under both the presence and absence o f COX-2 stimulators in normal intestinal 
cell line, IEC-6 cells. The inhibitors o f  extracellular-signal-regulated protein kinase
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(ERK), and p38 MAP kinase inhibit the flufenamic acid-induced COX-2 expression, 
suggesting that flufenamic acid-induced COX-2 expression is at least partly mediated 
through activation o f MAPKs in IEC-6 cells. TNFa-induced activation o f NF-kB was 
suppressed by flufenamic acid or sulindac sulfide. However, these NSAIDs did not 
appear to affect TNFa-induced COX-2 expression in IEC-6 cells. This may be due to 
two opposing effects: one is induction o f  COX-2 by NSAIDs and the other is induction 
of TNFa-induced COX-2 expression by NSAIDs.
In conclusion, the results o f these studies suggest that the anti-inflammatory and 
immunomodulating effects of n-3 PUFAs are mediated through not only inhibition of 
COX-2 enzyme activity but also suppression o f COX-2 expression. Moreover, our in 
vivo and in vitro studies suggest that the suppression o f tumor growth by dietary n-3 
PUFAs is mediated through COX-independent pathways. Results from the present 
study indicate that some NSAIDs show differential effects on mitogen-stimulated COX- 
2 expression in normal cells and cancer cells.
Further studies are needed to resolve how n-3 PUFAs and NSAIDs exert their 
anti-inflammatory effects and inhibitory effects on tumor growth. The molecular 
targets o f n-3 PUFAs and NSAIDs mediating the anti-inflammatory effects need to be 
identified. Recently, it was shown that PUFAs and NSAIDs bind and activate PPARs. 
Thus, it needs to be determined whether PPARs mediate anti-inflammatory and anti­
neoplastic effects o f n-3 PUFAs and NSAIDs.
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APPENDIX 1
PATHWAY OF PROSTAGLANDIN BIOSYNTHESIS
H O R M O N E
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Figure A l. Pathway of prostaglandin biosynthesis by COX-1 and COX-2 (Smith 
and DeWitt, 1996)
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Figure A2. Tetracycline-regulated expression of the COX protein and PGE2 
production in human colon cancer cells (HCT-116) stably transfected with COX-1- 
flag (A) or COX-2-flag (C). Whole cell lysates from stable clonal cells were 
immunoprecipitated with polyclonal anti-Flag antibodies and immunoblotted with COX 
antibodies (A, C). COX enzyme activity (B, D) was determined by radioimmunoassay 
for PGE2 in the same stable clonal cells used at (A) or (C). Lane 1, no DNA transfected 
cells; Lane 2, pLinx vector transfected cells; Lane 3, pLinx-COX-lor COX-2 
transfected cells with no tetracyclin; Lane 4, pLinx-COX-lor COX-2 transfected cells 
with tetracyclin. *, P<0.05.
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®  PPARp Immunoblot
PPARy Immunoblot
1 2 3 4 5 6 7 8
Figure A3. Expression of peroxisome proliferator-activated receptors (PPARs) 
subtypes in various cell types. Whole cell lysates from various cells were analyzed by 
PPARa (A), PPARp (B), or PPARy (C) immunoblot. Lane 1, IEC-6 ; Lane 2, 
RAW264.7; Lane 3, NIH3T3; Lane 4, HT-29; Lane 5, HCT-116; Lane 6 , MCF-7; Lane 
7. MCF-10A; Lane 8 , 293 cells.
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APPENDIX 4 
COMPONENTS FOR BUFFERS AND GELS
COX Lysis Buffer
2 x Laemmli Buffer
4 x Laemmli Buffer
PT Lysis Buffer
RIPA Buffer
50 mM Tris-Cl (pH 7.4), ImM sodium diethyldithiocarbamic 
acid (Na-DDTC), 10 mM EDTA, 1% Tween20, 1% Triton X- 
100, 10 pg/ml leupeptin, ImM phenylmethylsulfonyl fluoride 
(PMSF).
125mM Tris-Cl (pH6 .8 ), 20 % (v/v) glycerol, 5 % (w/v) SDS, 
10 % (v/v) P-mercaptoethano 1, 0.016 % (w/v) bromophenol 
blue.
250mM Tris-Cl (pH6 .8 ), 40 % (v/v) glycerol, 10 % (w/v) SDS, 
20 % (v/v) p-mercaptoethanol, 0.032 % (w/v) bromophenol 
blue.
20mM Tris-Cl (pH8.0), 137mM NaCl, 10 % (v/v) Glycerol, 
1% (v/v) Triton X-100, ImM ), ImM Na3VC>4, 2 mM EDTA, 
ImM phenylmethylsulfonyl fluoride (PMSF), 10 pg/ml 
leupeptin, 1 0  fig/ml aprotinin.
50mM Tris-Cl (pH7.4), 1% (v/v) Nonidet P-40, 0.25 % (w/v) 
Sodium deoxycholate, 150mMNaCl, ImM EGTA, ImM
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phenylmethylsulfonyl fluoride (PMSF), ImM Na3VC>4, 
1 0  pg/ml leupeptin, 1 0  pg/ml aprotinin.
Stripping Buffer 2% (w/v) SDS, 50mM Tris-Cl (pH6 .8 ), lOOmM
(pH 6.5)
P-mercaptoethanol.
TBS-T (pH7.6) 1 OmM Tris-Cl, 150mM NaCl, 0.05% (v/v) Tween 20.
TE 1 OmM Tris-Cl (pH 7.6), 1 mM EDTA
Transfer Buffer lOmM NaHCC>3, 3mM Na2C0 3 , 20% (v/v) methanol
(pH9.9)
Polyacrylamide gel 8  % Acrylamide/Bis solution, 400 mM Tris-HCl (pH 8 .8 ),
10 % glycerol, 1 mM EDTA, 0.2 % SDS, 0.1 % APS
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ATF2 Activating transcription factor 2
ATP Adenosine triphosphate




CRE Cyclic AMP response element





EFA Essential fatty acid
EGF Epithermal growth factor
EPA Eicosapentaenoic acid
ERKs Extracellular signal-regulated kinases
FBS Fetal bovine serum
GAPDH Glyceraldehyde-3 -phosphate dehydrogenase
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Ik B cc Inhibitory kappa B alpha
IKK IkB kinase
IL-1 Interleukin-1
iNOS Inducible nitric oxide synthase
IP Immunoprecipitation
IRAK IL-lR-associated kinase






MAPKs Mitogen-activated protein kinases
MAPKK MAP kinase kinaset
MAPKKK MAP kinase kinase kinase
MEK-1 A synonym of MAPKK-1
MEK-2 A synonym of MAPKK-2
MHC Major histocompatibility complex
NFDM Non-fat dried milk
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NF-kB Nuclear factor-kappa B
NIK NF-KB-inducing kinase
NO Nitric oxide
NSAIDs Non-steroidal anti-inflammatory drugs
OA Oleic acid
PA Palmitic aicd
PAK p2 1 -activated kinase
PBS Phosphate-buffered saline
PDGF Platelet derived growth factor
PGs Prostaglandins
p g d 2 Prostaglandin D2
p g e 2 Prostaglandin E2
p g f 2 Prostaglandin F2
p g h 2 Prostaglandin H2
p g i 2 Prostaglandin I2
PHA Phytohemagglutinin
PKC Protein kinase C
PKs Protein kinases
PMA Phorbol 12-myri state 13-acetate
PMSF Phenylmethylsulfonicfluoride
PPARs Peroxisome proliferator-activated receptors
PPRE PPAR response element
PT Phosphotyrosine
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PUFA Polyunsaturated fatty acid
RIP Receptor interacting protein
RSK Ribosomal S6  protein kinase
SA Stearic acid
SAPKs Stress-activated protein kinases
SDS Sodium dodecyl sulfate
TF Transcription factor
Tlr4 Toll-like receptor 4
TNFa Tumor necrosis factor alpha
TRAFs TNF-receptor associated factors
t x a 2 Thromboxane A2
I l l
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